

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

Hill-Rom Holdings, Inc.

Form 10-Q

April 26, 2019

false--09-30Q220192019-03-3110-Q000004751866772747falseLarge Accelerated FilerHill-Rom Holdings, Inc.falseHRCP8YP7YP7Y0.200.380.210.410.006750.070.06750.00000 0000047518 2018-10-01 2019-03-31 0000047518 2019-04-22 0000047518 2018-01-01 2018-03-31 0000047518 2017-10-01 2018-03-31 0000047518 2019-01-01 2019-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000047518 2019-03-31 0000047518 2018-09-30 0000047518 us-gaap:RetainedEarningsMember 2018-09-30 0000047518 us-gaap:CommonStockMember 2018-09-30 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000047518 us-gaap:TreasuryStockMember 2018-09-30 0000047518 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000047518 2017-12-31 0000047518 2017-09-30 0000047518 us-gaap:NoncontrollingInterestMember hrc:VIEActivityMember 2018-03-31 0000047518 us-gaap:TreasuryStockMember 2017-12-31 0000047518 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0000047518 us-gaap:ParentMember 2018-01-01 2018-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000047518 us-gaap:NoncontrollingInterestMember 2018-03-31 0000047518 us-gaap:TreasuryStockMember 2018-03-31 0000047518 hrc:VIEActivityMember 2018-03-31 0000047518 us-gaap:ParentMember 2017-12-31 0000047518 us-gaap:CommonStockMember 2018-03-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000047518 us-gaap:CommonStockMember 2017-12-31 0000047518 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000047518 us-gaap:NoncontrollingInterestMember 2017-12-31 0000047518 us-gaap:RetainedEarningsMember 2017-12-31 0000047518 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000047518 2018-03-31 0000047518 us-gaap:ParentMember 2018-03-31 0000047518 us-gaap:RetainedEarningsMember 2018-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000047518 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000047518 us-gaap:RetainedEarningsMember 2019-03-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000047518 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000047518 us-gaap:CommonStockMember 2018-12-31 0000047518 us-gaap:CommonStockMember 2019-03-31 0000047518 us-gaap:TreasuryStockMember 2018-12-31 0000047518 2018-12-31 0000047518 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000047518 us-gaap:RetainedEarningsMember 2018-12-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000047518 us-gaap:TreasuryStockMember 2019-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000047518 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-03-31 0000047518 us-gaap:RetainedEarningsMember 2018-10-01 2019-03-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2019-03-31 0000047518 us-gaap:CommonStockMember 2018-10-01 2019-03-31 0000047518 us-gaap:TreasuryStockMember 2018-10-01 2019-03-31 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2019-03-31 0000047518 us-gaap:AccountingStandardsUpdate201616Member 2018-10-01 2019-03-31 0000047518 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-10-01 2019-03-31 0000047518 us-gaap:AccountingStandardsUpdate201409Member 2018-10-01 2019-03-31 0000047518 us-gaap:ParentMember 2018-10-01 2019-03-31 0000047518 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2018-03-31 0000047518 us-gaap:ParentMember 2017-10-01 2018-03-31 0000047518 us-gaap:CommonStockMember 2017-10-01 2018-03-31 0000047518 us-gaap:RetainedEarningsMember 2017-10-01 2018-03-31 0000047518 us-gaap:CommonStockMember 2017-09-30 0000047518 us-gaap:NoncontrollingInterestMember 2017-09-30 0000047518 hrc:VIEActivityMember 2017-12-31 0000047518 us-gaap:TreasuryStockMember 2017-10-01 2018-03-31 0000047518 us-gaap:TreasuryStockMember 2017-09-30 0000047518 us-gaap:RetainedEarningsMember 2017-09-30 0000047518 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000047518 us-gaap:ParentMember 2017-09-30 0000047518 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0000047518

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

us-gaap:NoncontrollingInterestMember hrc:VIEActivityMember 2017-12-31 0000047518
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-01 2018-03-31 0000047518
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-03-31 0000047518
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
2018-10-01 0000047518 us-gaap:RetainedEarningsMember 2018-10-01 0000047518 country:US 2018-10-01
2019-03-31 0000047518 country:US us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
2019-01-01 2019-03-31 0000047518 country:US hrc:FrontLineCareMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember us-gaap:NonUsMember hrc:PatientSupportSystemsMember 2018-10-01
2019-03-31 0000047518 country:US hrc:PatientSupportSystemsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember us-gaap:NonUsMember hrc:FrontLineCareMember 2019-01-01 2019-03-31
0000047518 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember hrc:SurgicalSolutionsMember 2019-01-01
2019-03-31 0000047518 hrc:FrontLineCareMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
hrc:SurgicalSolutionsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
2018-10-01 2019-03-31 0000047518 us-gaap:NonUsMember hrc:SurgicalSolutionsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember us-gaap:NonUsMember hrc:FrontLineCareMember 2018-10-01 2019-03-31
0000047518 hrc:PatientSupportSystemsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:NonUsMember hrc:FrontLineCareMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:FrontLineCareMember 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember country:US hrc:PatientSupportSystemsMember 2018-10-01 2019-03-31
0000047518 us-gaap:NonUsMember hrc:SurgicalSolutionsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
country:US hrc:SurgicalSolutionsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember us-gaap:NonUsMember hrc:SurgicalSolutionsMember 2018-10-01 2019-03-31
0000047518 country:US hrc:SurgicalSolutionsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:SurgicalSolutionsMember 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:SurgicalSolutionsMember 2018-10-01 2019-03-31 0000047518 country:US
hrc:PatientSupportSystemsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
2019-01-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember country:US hrc:FrontLineCareMember
2019-01-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember
hrc:PatientSupportSystemsMember 2019-01-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember
country:US hrc:PatientSupportSystemsMember 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember country:US hrc:SurgicalSolutionsMember 2018-10-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:FrontLineCareMember 2018-10-01 2019-03-31 0000047518
hrc:FrontLineCareMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01
2019-03-31 0000047518 us-gaap:NonUsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:PatientSupportSystemsMember 2018-10-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember country:US hrc:SurgicalSolutionsMember 2019-01-01 2019-03-31 0000047518
hrc:PatientSupportSystemsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member
2019-01-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember country:US hrc:FrontLineCareMember
2018-10-01 2019-03-31 0000047518 us-gaap:NonUsMember hrc:PatientSupportSystemsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

country:US 2019-01-01 2019-03-31 0000047518 country:US
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:NonUsMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01
2019-03-31 0000047518 country:US hrc:FrontLineCareMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
us-gaap:NonUsMember 2019-01-01 2019-03-31 0000047518 us-gaap:NonUsMember hrc:FrontLineCareMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:NonUsMember 2018-10-01 2019-03-31 0000047518 hrc:SurgicalSolutionsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:PatientSupportSystemsMember 2019-01-01 2019-03-31 0000047518
us-gaap:NonUsMember hrc:PatientSupportSystemsMember
us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-10-01 2019-03-31 0000047518
hrc:CurrentandNoncurrentLiabilitiesMember 2019-03-31 0000047518 hrc:CurrentandNoncurrentLiabilitiesMember
2018-09-30 0000047518 us-gaap:OtherAssetsMember 2019-03-31 0000047518 us-gaap:OtherCurrentAssetsMember
2019-03-31 0000047518 us-gaap:OtherAssetsMember 2018-09-30 0000047518 2019-04-01 2019-04-01 0000047518
2019-04-01 0000047518 hrc:MEMSMember 2017-10-01 2018-09-30 0000047518 2018-10-01 2018-10-01
0000047518 hrc:MortaraMember us-gaap:TradeNamesMember 2018-10-01 2019-03-31 0000047518
hrc:MortaraMember us-gaap:CustomerRelationshipsMember 2018-10-01 2019-03-31 0000047518
hrc:MortaraMember us-gaap:DevelopedTechnologyRightsMember 2018-10-01 2019-03-31 0000047518
hrc:PatientSupportSystemsMember 2018-09-30 0000047518 hrc:FrontLineCareMember 2018-10-01 2019-03-31
0000047518 hrc:FrontLineCareMember 2019-03-31 0000047518 hrc:SurgicalSolutionsMember 2018-09-30
0000047518 hrc:PatientSupportSystemsMember 2019-03-31 0000047518 hrc:FrontLineCareMember 2018-09-30
0000047518 hrc:SurgicalSolutionsMember 2019-03-31 0000047518 hrc:PatientSupportSystemsMember 2018-10-01
2019-03-31 0000047518 hrc:SurgicalSolutionsMember 2018-10-01 2019-03-31 0000047518
hrc:SeniorSecuredTermLoanAMember 2018-09-30 0000047518
hrc:UnsecuredSevenPercentDebenturesDueOnFebruary152024Member 2019-03-31 0000047518
us-gaap:RevolvingCreditFacilityMember 2018-09-30 0000047518
hrc:UnsecuredSevenPercentDebenturesDueOnFebruary152024Member 2018-09-30 0000047518
hrc:UnsecuredSixPointSevenFivePercentDebenturesDueOnDecember152027Member 2018-09-30 0000047518
hrc:SecuritizationProgramMember 2019-03-31 0000047518 us-gaap:RevolvingCreditFacilityMember 2019-03-31
0000047518 hrc:SeniorUnsecuredNotesDueSeptember1Member 2019-03-31 0000047518
hrc:SeniorUnsecured5.00NotesdueonFebruary142025Member 2019-03-31 0000047518
hrc:OtherFinancingAgreementsMember 2019-03-31 0000047518 hrc:NoteSecuritizationFacilityMember 2018-09-30
0000047518 hrc:SecuritizationProgramMember 2018-09-30 0000047518
hrc:SeniorUnsecuredNotesDueSeptember1Member 2018-09-30 0000047518
hrc:SeniorUnsecured5.00NotesdueonFebruary142025Member 2018-09-30 0000047518
hrc:NoteSecuritizationFacilityMember 2019-03-31 0000047518 hrc:SeniorSecuredTermLoanAMember 2019-03-31
0000047518 hrc:UnsecuredSixPointSevenFivePercentDebenturesDueOnDecember152027Member 2019-03-31
0000047518 hrc:OtherFinancingAgreementsMember 2018-09-30 0000047518 us-gaap:ScenarioForecastMember
2019-12-31 0000047518 hrc:NoteSecuritizationFacilityMember
us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-31 0000047518
us-gaap:ForeignExchangeForwardMember 2019-03-31 0000047518
us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2018-10-01 2019-03-31 0000047518
us-gaap:OtherCurrentLiabilitiesMember us-gaap:CurrencySwapMember 2019-03-31 0000047518
us-gaap:InterestRateSwapMember 2019-03-31 0000047518 us-gaap:CurrencySwapMember 2019-03-31 0000047518
us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember 2018-09-30 0000047518
hrc:SeniorUnsecured5.00NotesdueonFebruary142025Member 2017-02-28 0000047518
us-gaap:CurrencySwapMember 2018-10-01 2019-03-31 0000047518 us-gaap:CurrencySwapMember 2019-01-01
2019-03-31 0000047518 hrc:SecuritizationProgramMember 2018-05-31 0000047518
hrc:SeniorSecuredRevolvingCreditFacilityMember 2018-10-01 2019-03-31 0000047518
hrc:NoteSecuritizationFacilityMember 2018-05-31 0000047518 hrc:SecuritizationProgramMember

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

us-gaap:LondonInterbankOfferedRateLIBORMember 2019-03-31 0000047518
hrc:NoteSecuritizationFacilityMember 2018-05-01 2018-05-31 0000047518 us-gaap:OtherAssetsMember
us-gaap:InterestRateSwapMember 2019-03-31 0000047518
us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-03-31 0000047518
hrc:SecuritizationProgramMember 2018-05-01 2018-05-31 0000047518 us-gaap:UnsecuredDebtMember 2019-03-31
0000047518 us-gaap:UnsecuredDebtMember 2018-09-30 0000047518 hrc:SeniorSecuredTermLoanAMember
2018-10-01 2019-03-31 0000047518 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-10-01
2018-03-31 0000047518 us-gaap:CostOfGoodsTotalMember 2019-01-01 2019-03-31 0000047518
us-gaap:CostOfGoodsTotalMember 2018-10-01 2019-03-31 0000047518 us-gaap:CostOfGoodsTotalMember
2017-10-01 2018-03-31 0000047518 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01
2019-03-31 0000047518 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-10-01 2019-03-31
0000047518 us-gaap:CostOfGoodsTotalMember 2018-01-01 2018-03-31 0000047518
us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31
0000047518 us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31
0000047518 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-03-31 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0000047518
us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000047518
us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31
0000047518 us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0000047518
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-01 2017-12-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2018-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000047518
us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31
0000047518 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31
0000047518 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000047518
us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31
0000047518 us-gaap:CurrencySwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000047518
us-gaap:ForeignExchangeContractMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000047518
us-gaap:CurrencySwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

0000047518 us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000047518
us-gaap:ForeignExchangeContractMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31
0000047518 us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000047518
us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000047518 us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-10-01 2018-03-31 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2017-10-01 2018-03-31 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-10-01 2018-03-31
0000047518 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-10-01
2018-03-31 0000047518 us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-10-01 2018-03-31
0000047518 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-09-30
0000047518 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-09-30 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2017-09-30 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-01 2019-03-31 0000047518
us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:ForeignExchangeContractMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000047518
us-gaap:ForeignExchangeContractMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2019-03-31 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2018-10-01 0000047518
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2018-10-01
0000047518 us-gaap:ForeignExchangeForwardMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000047518
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-09-30 0000047518
us-gaap:ForeignExchangeContractMember 2018-10-01 2018-10-01 0000047518 us-gaap:InterestRateSwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:ForeignExchangeForwardMember 2018-10-01 2018-10-01 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0000047518
us-gaap:AccumulatedTranslationAdjustmentMember 2018-10-01 2018-10-01 0000047518
us-gaap:InterestRateSwapMember 2018-10-01 2018-10-01 0000047518
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000047518

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-03-31 0000047518
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-03-31
0000047518 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-03-31
0000047518 us-gaap:CurrencySwapMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-10-01 2018-03-31 0000047518
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-10-01 2019-03-31
0000047518 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-10-01 2019-03-31 0000047518
us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember
us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-10-01 2018-03-31
0000047518 us-gaap:FacilityClosingMember hrc:SiteConsolidationMember 2017-10-01 2018-03-31 0000047518
us-gaap:EmployeeSeveranceMember hrc:BusinessOptimizationMember 2017-10-01 2018-03-31 0000047518
hrc:BusinessOptimizationMember 2017-10-01 2018-03-31 0000047518 us-gaap:OtherRestructuringMember
hrc:GlobalRestructuringProgramMember 2018-10-01 2019-03-31 0000047518 us-gaap:EmployeeSeveranceMember
hrc:SiteConsolidationMember 2017-10-01 2018-03-31 0000047518 us-gaap:EmployeeSeveranceMember
hrc:BusinessOptimizationMember 2018-01-01 2018-03-31 0000047518 us-gaap:EmployeeSeveranceMember
hrc:BusinessOptimizationMember 2018-10-01 2019-03-31 0000047518
hrc:IntegrationandBusinessRealignmentMember 2018-10-01 2019-03-31 0000047518
us-gaap:EmployeeSeveranceMember hrc:SiteConsolidationMember 2018-10-01 2019-03-31 0000047518
us-gaap:FacilityClosingMember hrc:SiteConsolidationMember 2019-03-31 0000047518
hrc:IntegrationandBusinessRealignmentMember 2018-01-01 2018-03-31 0000047518
hrc:IntegrationandBusinessRealignmentMember 2017-10-01 2018-03-31 0000047518
hrc:BusinessOptimizationMember 2018-01-01 2018-03-31 0000047518 us-gaap:EmployeeSeveranceMember
hrc:BusinessOptimizationMember 2019-01-01 2019-03-31 0000047518 2015-06-30 0000047518
us-gaap:FacilityClosingMember hrc:SiteConsolidationMember 2018-01-01 2018-03-31 0000047518
hrc:IntegrationandBusinessRealignmentMember 2019-01-01 2019-03-31 0000047518
us-gaap:EmployeeSeveranceMember hrc:SiteConsolidationMember 2018-01-01 2018-03-31 0000047518
hrc:BusinessOptimizationMember 2019-01-01 2019-03-31 0000047518 us-gaap:FacilityClosingMember
hrc:SiteConsolidationMember 2019-01-01 2019-03-31 0000047518 us-gaap:FacilityClosingMember
hrc:SiteConsolidationMember 2018-10-01 2019-03-31 0000047518 2018-10-01 2018-12-31 0000047518 2018-01-01
0000047518 us-gaap:CommonStockMember 2013-09-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember 2018-01-01 2018-03-31 0000047518 us-gaap:OperatingSegmentsMember
hrc:SurgicalSolutionsMember 2018-01-01 2018-03-31 0000047518 us-gaap:OperatingSegmentsMember
hrc:PatientSupportSystemsMember 2018-01-01 2018-03-31 0000047518 us-gaap:CorporateAndOtherMember
2017-10-01 2018-03-31 0000047518 us-gaap:OperatingSegmentsMember hrc:FrontLineCareMember 2017-10-01
2018-03-31 0000047518 us-gaap:OperatingSegmentsMember hrc:SurgicalSolutionsMember 2017-10-01 2018-03-31
0000047518 us-gaap:CorporateAndOtherMember 2018-01-01 2018-03-31 0000047518
us-gaap:OperatingSegmentsMember hrc:FrontLineCareMember 2018-01-01 2018-03-31 0000047518
us-gaap:OperatingSegmentsMember 2017-10-01 2018-03-31 0000047518 us-gaap:CorporateAndOtherMember
2019-01-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000047518
us-gaap:OperatingSegmentsMember 2018-10-01 2019-03-31 0000047518 us-gaap:CorporateAndOtherMember
2018-10-01 2019-03-31 0000047518 us-gaap:OperatingSegmentsMember hrc:PatientSupportSystemsMember
2017-10-01 2018-03-31 0000047518 srt:MaximumMember us-gaap:UninsuredRiskMember 2019-03-31
iso4217:USD iso4217:USD xbrli:shares hrc:derivative xbrli:shares xbrli:pure hrc:site

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 10-Q

(Mark One)

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, 2019

OR

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ____ to ____

Commission File No. 1-6651

HILL-ROM HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Indiana

(State or other jurisdiction of incorporation or organization)

35-1160484

(I.R.S. Employer Identification No.)

130 E. Randolph St., Suite 1000

Chicago, IL

(Address of principal executive offices)

60601

(Zip Code)

(312) 819-7200

(Registrant's telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Common Stock, without par value – 66,772,747 shares as of April 22, 2019.

Table of Contents

HILL-ROM HOLDINGS, INC.

INDEX TO FORM 10-Q

	<u>Page</u>
PART I - FINANCIAL INFORMATION	
<u>Item 1 - Financial Statements</u>	
<u>Condensed Consolidated Statements of Income (Unaudited)</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</u>	4
<u>Condensed Consolidated Balance Sheets (Unaudited)</u>	5
<u>Condensed Consolidated Statements of Cash Flows (Unaudited)</u>	6
<u>Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</u>	7
<u>Note 1. Summary of Significant Accounting Policies</u>	9
<u>Note 2. Revenue Recognition</u>	13
<u>Note 3. Supplementary Balance Sheet Information</u>	17
<u>Note 4. Business Combinations</u>	17
<u>Note 5. Goodwill</u>	18
<u>Note 6. Financing Agreements</u>	18
<u>Note 7. Retirement and Postretirement Plans</u>	21
<u>Note 8. Other Comprehensive Income (Loss)</u>	22
<u>Note 9. Special Charges</u>	25
<u>Note 10. Income Taxes</u>	26
<u>Note 11. Earnings per Common Share</u>	27
<u>Note 12. Common Stock</u>	27
<u>Note 13. Guarantees</u>	27
<u>Note 14. Segment Reporting</u>	28
<u>Note 15. Commitments and Contingencies</u>	29

<u>Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>30</u>
<u>Item 3 - Quantitative and Qualitative Disclosures About Market Risks</u>	<u>40</u>
<u>Item 4 - Controls and Procedures</u>	<u>40</u>
PART II - OTHER INFORMATION	
<u>Item 1 - Legal Proceedings</u>	<u>41</u>
<u>Item 1A - Risk Factors</u>	<u>41</u>
<u>Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>41</u>
<u>Item 6 - Exhibits</u>	<u>42</u>
<u>SIGNATURES</u>	<u>43</u>

Table of Contents**PART I – FINANCIAL INFORMATION****Item 1. FINANCIAL STATEMENTS**

Hill-Rom Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Income (Unaudited)
(In millions, except per share data)

	Quarter Ended		Year to Date Ended	
	March 31		March 31	
	2019	2018	2019	2018
Net Revenue				
Product sales and service	\$636.5	\$610.7	\$1,248.1	\$1,185.9
Rental revenue	77.7	99.8	149.6	194.3
Total net revenue	714.2	710.5	1,397.7	1,380.2
Cost of Net Revenue				
Cost of goods sold	322.7	313.7	639.0	617.8
Rental expenses	38.9	46.4	76.1	92.4
Total cost of net revenue	361.6	360.1	715.1	710.2
Gross Profit	352.6	350.4	682.6	670.0
Research and development expenses	36.6	34.7	69.8	67.0
Selling and administrative expenses	231.2	232.7	449.2	454.4
Special charges	3.5	36.9	11.5	50.4
Operating Profit	81.3	46.1	152.1	98.2
Interest expense	(21.8)	(24.2)	(43.1)	(47.3)
Investment income and other, net	1.2	(0.4)	1.3	1.4
Income Before Income Taxes	60.7	21.5	110.3	52.3
Income tax expense (benefit)	11.2	(7.0)	18.6	(64.5)
Net Income	\$49.5	\$28.5	\$91.7	\$116.8
Net Income per Basic Common Share	\$0.74	\$0.43	\$1.37	\$1.77
Net Income per Diluted Common Share	\$0.74	\$0.42	\$1.36	\$1.73
Average Basic Common Shares Outstanding (in thousands)	66,696	66,192	66,866	66,040
Average Diluted Common Shares Outstanding (in thousands)	67,344	67,597	67,525	67,508

See Notes to Condensed Consolidated Financial Statements (unaudited)

Table of Contents**Hill-Rom Holdings, Inc. and Subsidiaries****Condensed Consolidated Statements of Comprehensive Income (Unaudited)***(In millions)*

	Quarter Ended March 31		Year to Date Ended March 31	
	2019	2018	2019	2018
Net Income	\$49.5	\$28.5	\$91.7	\$116.8
Other Comprehensive Income (Loss), net of tax (Note 8):				
Derivative instruments designated as hedges	(1.9)	7.9	(5.6)	11.3
Foreign currency translation adjustment	(3.6)	16.5	(17.2)	22.6
Change in pension and postretirement defined benefit plans	0.5	0.8	0.9	1.6
Total Other Comprehensive Income (Loss), net of tax	(5.0)	25.2	(21.9)	35.5
Total Comprehensive Income	\$44.5	\$53.7	\$69.8	\$152.3

See Notes to Condensed Consolidated Financial Statements (unaudited)

Table of Contents**Hill-Rom Holdings, Inc. and Subsidiaries**
Condensed Consolidated Balance Sheets (Unaudited)*(In millions)*

	March 31,	September 30,
	2019	2018
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 187.0	\$ 183.0
Trade accounts receivable, net of allowances (Note 3)	581.8	580.7
Inventories, net of reserves (Note 3)	293.8	291.7
Other current assets	118.4	100.2
Total current assets	1,181.0	1,155.6
Property, plant and equipment, net (Note 3)	313.3	328.3
Goodwill (Note 5)	1,732.9	1,738.3
Other intangible assets and software, net (Note 3)	1,012.0	1,027.7
Deferred income taxes (Notes 1 and 10)	34.0	35.0
Other assets	94.4	75.1
Total Assets	\$ 4,367.6	\$ 4,360.0
LIABILITIES		
Current Liabilities		
Trade accounts payable	\$ 169.9	\$ 177.3
Short-term borrowings (Note 6)	224.7	182.5
Accrued compensation	88.8	132.5
Accrued product warranties (Note 13)	24.5	20.5
Accrued rebates	42.3	42.5
Deferred revenue (Note 2)	81.7	40.0
Other current liabilities	65.4	67.1
Total current liabilities	697.3	662.4
Long-term debt (Note 6)	1,764.4	1,790.4
Accrued pension and postretirement benefits (Note 7)	68.2	69.3
Deferred income taxes (Notes 1 and 10)	165.7	181.3
Other long-term liabilities	73.2	40.4
Total Liabilities	2,768.8	2,743.8
Commitments and Contingencies (Note 15)		
SHAREHOLDERS' EQUITY		
Common stock (Notes 3 and 12)	4.4	4.4
Additional paid-in capital	619.9	602.9
Retained earnings	1,935.2	1,876.2
Accumulated other comprehensive loss (Note 8)	(140.3)	(113.0)
Treasury stock, at cost (Note 3)	(820.4)	(754.3)
Total Shareholders' Equity	1,598.8	1,616.2
Total Liabilities and Shareholders' Equity	\$ 4,367.6	\$ 4,360.0

See Notes to Condensed Consolidated Financial Statements (unaudited)

Table of Contents

Hill-Rom Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In millions)

	Year to Date	
	March 31	
	2019	2018
Operating Activities		
Net income	\$91.7	\$116.8
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization of property, plant, equipment and software	36.4	45.1
Acquisition-related intangible asset amortization	53.0	53.7
Amortization of debt discounts and issuance costs	3.2	3.7
Benefit for deferred income taxes	(8.2)	(89.2)
(Gain) loss on disposal of property, equipment leased to others, intangible assets, and impairments	(0.2)	(0.6)
Loss on disposition of businesses	—	22.4
Stock compensation	16.9	15.8
Change in working capital excluding cash, current debt, acquisitions and dispositions:		
Trade accounts receivable	24.0	45.7
Inventories	(1.5)	(29.0)
Other current assets	3.7	(37.9)
Trade accounts payable	(6.6)	(8.7)
Accrued expenses and other liabilities	(53.9)	(35.8)
Other, net	(0.3)	23.6
Net cash provided by operating activities	158.2	125.6
Investing Activities		
Purchases of property, plant, equipment and software	(31.4)	(51.4)
Proceeds on sale of property and equipment leased to others	3.1	3.7
Payment for acquisition of intangible assets	(17.1)	—
Payments for acquisitions of investments	(26.6)	—
Proceeds on sale of business	—	1.0
Other, net	0.2	(1.0)
Net cash used in investing activities	(71.8)	(47.7)
Financing Activities		
Payments of long-term debt	(0.1)	(54.9)
Borrowings on Revolving Credit Facility	110.0	75.0
Payments on Revolving Credit Facility	(105.0)	(95.0)
Borrowings on Securitization Program	4.9	51.4
Payments on Securitization Program	(4.9)	(37.3)
Borrowings on Note Securitization Facility	37.5	—
Payments on Note Securitization Facility	(28.4)	—
Payments of cash dividends	(27.4)	(25.1)
Proceeds on exercise of stock options	8.6	10.5
Stock repurchases for stock award withholding obligations	(4.0)	(4.4)
Stock repurchases in the open market	(75.0)	—
Other, net	3.7	4.0
Net cash used in financing activities	(80.1)	(75.8)
Effect of exchange rate changes on cash and cash equivalents	(2.3)	5.1
Net Cash Flows	4.0	7.2
Cash and Cash Equivalents:		

At beginning of period	183.0	231.8
At end of period	\$187.0	\$239.0
<i>See Notes to Condensed Consolidated Financial Statements (unaudited)</i>		

Table of Contents
Hill-Rom Holdings, Inc. and Subsidiaries
Condensed Consolidated Statements of Shareholders' Equity (Unaudited)
(In millions, except share amounts)

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock in Treasury		Total Shareholders' Equity
	Shares Outstanding	Amount				Shares	Amount	
Balance as of December 31, 2018	66,657,887	\$ 4.4	\$ 606.9	\$ 1,899.9	\$ (135.3)	21,799,747	\$(824.4)	\$ 1,551.5
Net income	—	—	—	49.5	—	—	—	49.5
Other comprehensive income (loss), net of tax of \$1.4 million	—	—	—	—	(5.0)	—	—	(5.0)
Dividends (\$0.21 per common share)	—	—	0.1	(14.2)	—	—	—	(14.1)
Stock repurchases for stock award withholding obligations	(5,690)	—	—	—	—	5,690	(0.5)	(0.5)
Stock compensation on equity-classified awards	—	—	11.1	—	—	—	—	11.1
Stock option exercises	80,628	—	1.0	—	—	(80,628)	3.0	4.0
Vesting of stock awards	18,103	—	(0.7)	—	—	(18,103)	0.7	—
Shares issued under employee stock purchase plan	20,799	—	1.5	—	—	(20,799)	0.8	2.3
Balance as of March 31, 2019	66,771,727	\$ 4.4	\$ 619.9	\$ 1,935.2	\$ (140.3)	21,685,907	\$(820.4)	\$ 1,598.8
	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock in Treasury		Total Shareholders' Equity
	Shares Outstanding	Amount				Shares	Amount	
Balance as of September 30, 2018	67,256,112	\$ 4.4	\$ 602.9	\$ 1,876.2	\$ (113.0)	21,201,522	\$(754.3)	\$ 1,616.2
Cumulative effect of ASC 606 adoption, net of tax of \$4.8 million	—	—	—	(4.9)	—	—	—	(4.9)
Cumulative effect of ASU 2016-16 adoption, net of tax of \$0.2 million	—	—	—	(5.6)	—	—	—	(5.6)
Reclassification due to ASU 2018-02 adoption	—	—	—	5.4	(5.4)	—	—	—
Net income	—	—	—	91.7	—	—	—	91.7
Other comprehensive income (loss), net of tax of \$1.5 million	—	—	—	—	(21.9)	—	—	(21.9)
Dividends (\$0.41 per common share)	—	—	0.2	(27.6)	—	—	—	(27.4)
Stock repurchases for stock award withholding obligations	(43,135)	—	—	—	—	43,135	(4.0)	(4.0)
Stock repurchases in the open market	(792,264)	—	—	—	—	792,264	(75.0)	(75.0)
Stock compensation on equity-classified awards	—	—	16.9	—	—	—	—	16.9
Stock option exercises	178,203	—	2.0	—	—	(178,203)	6.6	8.6
Vesting of stock awards	130,567	—	(4.7)	—	—	(130,567)	4.7	—
Shares issued under employee stock purchase plan	42,244	—	2.6	—	—	(42,244)	1.6	4.2
Balance as of March 31, 2019	66,771,727	\$ 4.4	\$ 619.9	\$ 1,935.2	\$ (140.3)	21,685,907	\$(820.4)	\$ 1,598.8

Edgar Filing: Hill-Rom Holdings, Inc. - Form 10-Q

Table of Contents

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock in Treasury		Total Equity Attributable to Common Shareholders	Noncontrolling Interests	Total Shareholders' Equity
	Shares Outstanding	Amount				Shares	Amount			
Balance as of December 31, 2017	66,139,823	\$ 4.4	\$ 587.2	\$ 1,752.5	\$ (99.7)	22,317,811	\$(787.3)	\$ 1,457.1	\$ 7.0	\$ 1,464.1
Net income attributable to common shareholders	—	—	—	28.5	—	—	—	28.5	—	28.5
VIE activity	—	—	—	—	—	—	—	—	(7.0)	(7.0)
Other comprehensive income (loss), net of tax of (\$1.4) million	—	—	—	—	25.2	—	—	25.2	—	25.2
Dividends (\$0.20 per common share)	—	—	0.2	(13.4)	—	—	—	(13.2)	—	(13.2)
Stock repurchases for stock award withholding obligations	(10,437)	—	—	—	—	10,437	(0.9)	(0.9)	—	(0.9)
Stock compensation on equity-classified awards	—	—	9.4	—	—	—	—	9.4	—	9.4
Stock option exercises	73,906	—	(0.2)	—	—	(73,906)	2.6	2.4	—	2.4
Vesting of stock awards	27,679	—	(1.0)	—	—	(27,679)	1.0	—	—	—
Shares issued under employee stock purchase plan	21,092	—	1.1	—	—	(21,092)	0.8	1.9	—	1.9
Balance as of March 31, 2018	66,252,063	\$ 4.4	\$ 596.7	\$ 1,767.6	\$ (74.5)	22,205,571	\$(783.8)	\$ 1,510.4	\$ —	\$ 1,510.4

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Common Stock in Treasury		Total Equity Attributable to Common Shareholders	Noncontrolling Interests	Total Shareholders' Equity
	Shares Outstanding	Amount				Shares	Amount			
Balance as of September 30, 2017	65,813,794	\$ 4.4	\$ 584.4	\$ 1,676.2	\$ (110.0)	22,643,840	\$(796.8)	\$ 1,358.2	\$ 7.4	\$ 1,365.6
Net income attributable to common shareholders	—	—	—	116.8	—	—	—	116.8	—	116.8
VIE activity	—	—	—	—	—	—	—	—	(7.4)	(7.4)
Other comprehensive income (loss), net of tax of (\$3.7) million	—	—	—	—	35.5	—	—	35.5	—	35.5
Dividends (\$0.38 per common share)	—	—	0.3	(25.4)	—	—	—	(25.1)	—	(25.1)
Stock repurchases for stock award withholding obligations	(53,811)	—	—	—	—	53,811	(4.4)	(4.4)	—	(4.4)
Stock compensation on equity-classified awards	—	—	15.5	—	—	—	—	15.5	—	15.5
Stock option exercises	314,762	—	(0.6)	—	—	(314,762)	11.1	10.5	—	10.5
Vesting of stock awards	138,546	—	(4.9)	—	—	(138,546)	4.9	—	—	—
Shares issued under employee stock purchase plan	38,772	—	2.0	—	—	(38,772)	1.4	3.4	—	3.4
Balance as of March 31, 2018	66,252,063	\$ 4.4	\$ 596.7	\$ 1,767.6	\$ (74.5)	22,205,571	\$(783.8)	\$ 1,510.4	\$ —	\$ 1,510.4

See Notes to Condensed Consolidated Financial Statements (unaudited)

Table of Contents

Hill-Rom Holdings, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

Note 1. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

Unless the context otherwise requires, the terms “Hill-Rom,” “the Company,” “we,” “our” and “us” refer to Hill-Rom Holdings, Inc. and its wholly-owned subsidiaries. The unaudited Condensed Consolidated Financial Statements appearing in this Quarterly Report on Form 10-Q should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in Hill-Rom’s latest Annual Report on Form 10-K for the fiscal year ended September 30, 2018 (“2018 Form 10-K”) as filed with the United States (“U.S.”) Securities and Exchange Commission. The September 30, 2018 Condensed Consolidated Balance Sheet was derived from audited Consolidated Financial Statements, but does not include all disclosures required by accounting principles generally accepted in the United States. In the opinion of management, the Condensed Consolidated Financial Statements herein include all adjustments necessary to state fairly the financial position, results of operations and cash flows for the interim periods presented. Quarterly results are not necessarily indicative of annual results.

The Condensed Consolidated Financial Statements include the accounts of Hill-Rom and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of certain assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense in the period. Actual results could differ from those estimates. Examples of such estimates include, but are not limited to, income taxes (Notes 1 and 10), accounts receivable reserves (Note 3), accrued warranties (Note 13), goodwill (Note 5), pension expense (Note 7), and commitments and contingencies (Note 15).

Revenue Recognition

Revenue is recognized as performance obligations are satisfied, either at a point in time or over time, driven by the nature of the obligation that is contracted to be provided to our customers. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Certain of our contracts have multiple performance obligations. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. The majority of our capital equipment revenue is recognized at a point in time, primarily based on the transfer of title, except in circumstances where we are also required to install the equipment, for which revenue is recognized upon customer acceptance of the installation. Performance obligations involving the provision of services and revenue from rental usage of our products are recognized over the time period specified in the contractual arrangement with the customer. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation.

Revenue is presented net of several types of variable consideration including rebates, discounts and product returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is also used for certain types of variable consideration. These estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns.

Certain costs associated with obtaining a contract, which primarily comprise sales commissions earned by Company personnel, are capitalized until such time as the related performance obligations are completed and the related revenue is recognized.

Contract liabilities arise as a result of cash received from customers at inception of contracts or where the timing of billing for services precedes satisfaction of our performance obligations. Remaining performance obligations represent the portion of the contract price for which work has not been performed, primarily related to installation and service contracts.

Table of Contents

Taxes assessed by a governmental authority that are directly imposed on a revenue producing transaction between us and our customers, including but not limited to sales taxes, use taxes and value added taxes, are excluded from revenue and cost.

See Note 2 for additional information about revenue recognition.

Fair Value Measurements

Fair value measurements of our financial assets and liabilities are classified and disclosed in one of the following three categories:

Level 1: Financial instruments with unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets and liabilities.

Level 2: Financial instruments with observable inputs other than those included in Level 1 such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Financial instruments with unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Unobservable inputs reflect our own assumptions that market participants would use in pricing the asset or liability (including assumptions about risk). Unobservable inputs are developed based on the best information available in the circumstances, which might include our own data.

We record cash and cash equivalents, as disclosed on our Condensed Consolidated Balance Sheets, as Level 1 instruments and certain other derivatives and investments as either Level 2 or 3 instruments. Investments measured at Net Asset Value as a practical expedient are not categorized in the fair value hierarchy. Refer to Note 6 for disclosure of our debt instrument and interest rate swap fair values. There have not been significant changes in our classification of assets and liabilities in the fiscal quarter.

Income Taxes

Hill-Rom and its eligible subsidiaries file a consolidated U.S. income tax return. We file income tax returns in a number of jurisdictions for our foreign operations. We have a variety of deferred tax assets in numerous tax jurisdictions which are computed using an asset and liability approach to reflect the net tax effects of temporary differences between the financial reporting carrying amounts of assets and liabilities and the corresponding income tax amounts. These deferred tax assets are subject to periodic assessment as to recoverability. If it is determined that it is more likely than not that the benefits will not be realized, valuation allowances are recognized. In evaluating whether it is more likely than not that we would recover these deferred tax assets, future taxable income, the reversal of existing temporary differences and tax planning strategies are considered.

As of March 31, 2019, we had \$78.3 million of valuation allowances on deferred tax assets, on a tax-effected basis, primarily related to certain foreign deferred tax attributes that are not expected to be utilized. The valuation allowance was not materially impacted by the Tax Cuts and Jobs Act (the "Tax Act") enacted in the United States in December 2017. We believe that our estimates for the valuation allowances recorded against deferred tax assets are appropriate based on current facts and circumstances.

We account for uncertain income tax positions using a threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The difference between the tax benefit recognized in the financial statements for an uncertain income tax position and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit. See Note 10 for further details.

Recently Adopted Accounting Standards

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, *Revenue from Contracts with Customers* (“ASC 606”), which provides guidance for revenue recognition. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We adopted the new standard in the first quarter of fiscal 2019 using the modified retrospective approach. See Note 2 for additional information on the impacts of ASC 606 on our Condensed Consolidated Financial Statements.

In January 2016, the FASB issued ASU 2016-01, *Financial Instruments (Topic 825-10) – Recognition and Measurement of Financial Assets and Financial Liabilities*. This standard requires equity securities to be measured at fair value with changes in fair value recognized through net income and eliminated the cost method for equity securities without readily determinable fair values. In February 2018, the FASB issued ASU 2018-03, *Technical Corrections and Improvements to Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities*. This standard issued six technical corrections and improvements to clarify guidance in ASU 2016-01, which primarily impacted the accounting for equity

Table of Contents

investments, financial liabilities under fair value option, and the presentation and disclosure requirements of financial instruments. We adopted ASU 2016-01 and ASU 2018-03 prospectively in the first quarter of fiscal 2019 and the new updates did not have a material impact on our Condensed Consolidated Financial Statements. We applied the practicability election within this standard under which our investments in equities that are not accounted for under the consolidation or equity method of accounting guidance are valued at cost, less impairment, plus or minus observable price changes (in orderly transactions) of an identical or similar investment of the same issuer.

In August 2016, the FASB issued ASU 2016-15, *Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments*. The purpose of the standard is to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard addresses specific issues including debt prepayment and extinguishment costs, settlement of zero-coupon debt, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims and certain life insurance policies, distributions received from equity method investees, beneficial interests in securitization transactions, and the application of the predominance principle in separately identifiable cash flows. We adopted ASU 2016-15 in the first quarter of fiscal 2019 using a retrospective transition method and elected to continue to use the nature of distribution approach for distributions received from equity method investees. The adoption of ASU 2016-15 did not have a material impact on our Condensed Consolidated Financial Statements.

In October 2016, the FASB issued ASU 2016-16, *Intra-Entity Transfers of Assets Other Than Inventory (Topic 740)*. This standard requires immediate recognition of the income tax consequences of intercompany asset transfers other than inventory. We adopted ASU 2016-16 in the first quarter of fiscal 2019 using the modified retrospective approach with a cumulative effect adjustment directly to retained earnings. The cumulative effect of applying ASU 2016-16 was an adjustment to decrease prepaid taxes by \$5.8 million and increase deferred tax assets by \$0.2 million with a corresponding decrease to the opening balance of Retained earnings of \$5.6 million.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*. This standard requires that companies include amounts generally described as restricted cash and restricted cash equivalents, along with cash and cash equivalents, when reconciling the beginning-of-period and end-of-period amounts shown on the statement of cash flows. We retrospectively adopted ASU 2016-18 in the first quarter of fiscal 2019. ASU 2016-18 did not have a material impact on our Condensed Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-01, *Business Combinations (Topic 805): Clarifying the Definition of a Business*. This standard provides clarification on the definition of a business and provides guidance on whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. We adopted ASU 2017-01 in the first quarter of fiscal 2019. ASU 2017-01 did not have a material impact on our Condensed Consolidated Financial Statements.

In February 2017, the FASB issued ASU 2017-07, *Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*. This standard requires employers to include only the service cost component of net periodic pension cost in operating expenses, together with other employee compensation costs. The other components of net periodic pension cost, including interest cost, expected return on plan assets, amortization of prior service cost and settlement and curtailment effects, are to be included in non-operating expenses. The amendment allows a practical expedient that permits an employer to use the amounts disclosed in its pension and other postretirement benefit plan note for the prior comparative periods as the estimation basis for applying the retrospective presentation requirements. We adopted ASU 2017-07 in the first quarter of fiscal 2019 and applied the practical expedient upon adoption. ASU 2017-07 did not have a material impact on our Condensed Consolidated Financial Statements.

In February 2018, the FASB issued ASU 2018-02, *Income Statement – Reporting Comprehensive Income (Topic 220)*. The standard allows entities to reclassify tax effects stranded in accumulated other comprehensive income as a result of tax reform to retained earnings. We adopted ASU 2018-02 in the first quarter of fiscal 2019. As a result of the adoption of ASU 2018-02, we reclassified \$5.4 million from Accumulated other comprehensive income (loss) to Retained earnings. We applied the individual item approach for releasing income tax effects from Accumulated other comprehensive income (loss).

Recently Issued Accounting Standards

In February 2016, the FASB issued ASU 2016-02, *Leases (Topic 842)* and has subsequently issued related amendments, collectively referred to as “ASC 842”. ASC 842 is effective for our first quarter of fiscal 2020. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. Early adoption of the new lease standard is permitted. From the lessee’s perspective, the new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating,

Table of Contents

with classification affecting the pattern of expense recognition in the income statement for a lessee. From the lessor's perspective, the new standard requires a lessor to classify leases as either sales-type, finance or operating. A lease will be treated as a sale if it transfers all of the risks and rewards, as well as control of the underlying asset, to the lessee. If risks and rewards are conveyed without the transfer of control, the lease is treated as a finance lease. If the lessor does not convey risks and rewards or control, an operating lease results. We are currently in the process of evaluating the impact of ASC 842 on our Condensed Consolidated Financial Statements. Most of our operating lease commitments relate to manufacturing facilities, warehouse distribution centers, service centers and sales offices and are expected to continue to be classified as operating leases upon our adoption of ASC 842.

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326) - Measurement of Credit Losses of Financial Instruments*. This standard requires entities to measure credit losses for financial assets measured at amortized cost based on expected losses rather than incurred losses. For available-for-sale debt securities with unrealized losses, entities will be required to recognize credit losses through an allowance for credit losses. ASU 2016-03 is effective for our first quarter of fiscal 2021 and requires a prospective transition method. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In January 2017, the FASB issued ASU 2017-04, *Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment*. This standard eliminates Step 2 of the goodwill impairment test and requires a goodwill impairment to be measured as the amount by which a reporting unit's carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 is effective for our first quarter of fiscal 2021 and requires a prospective transition method. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*. The purpose of the standard is to improve the overall usefulness of fair value disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. ASU 2018-13 is effective for our first quarter of fiscal 2021 and requires the application of the prospective method of transition (for only the most recent interim or annual period presented in the initial fiscal year of adoption) to the new disclosure requirements for (1) changes in unrealized gains and losses included in other comprehensive income and (2) the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 also requires prospective application to any modifications to disclosures made because of the change to the requirements for the narrative description of measurement uncertainty. The effects of all other amendments made by ASU 2018-13 must be applied retrospectively to all periods presented. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-14, *Compensation – Retirement Benefits – Defined Benefit Plans – General (Topic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans*. The purpose of the standard is to improve the overall usefulness of defined benefit pension and other postretirement plan disclosures to financial statement users and reduce unnecessary costs to companies when preparing the disclosures. ASU 2018-14 is effective for our fourth quarter of fiscal 2021 and requires a retrospective transition method. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-15, *Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*. The update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting

arrangements that include an internal-use software license). ASU 2018-15 is effective for our first quarter of fiscal 2021 and allows a retrospective or a prospective transition method to all implementation costs incurred after the date of adoption. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In October 2018, the FASB issued ASU 2018-16, *Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes*. The purpose of the standard is to allow the use of the OIS rate based on the SOFR for hedge accounting purposes, which allows entities to designate changes in the fair values of fixed-rate financial assets or liabilities attributable to the OIS rate as the hedged risk. ASU 2018-16 is effective for our first quarter of fiscal 2020 and requires a prospective application. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

In November 2018, the FASB issued ASU 2018-18, *Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606*. The purpose of the standard is to (1) clarify that transactions between participants in a collaborative agreement should be accounted for under Topic 606 and (2) add unit-of-account guidance in Topic 808 to align with Topic 606. ASU 2018-18 is effective for our first quarter of fiscal 2020 and must be applied retrospectively to the first quarter of fiscal 2019,

Table of Contents

the date of initial application of Topic 606. Early adoption is permitted. We are currently in the process of evaluating the impact of adoption on our Condensed Consolidated Financial Statements.

Except as noted above, there have been no significant changes to our assessment of the impact of recently issued accounting standards included in Note 1 of our Consolidated Financial Statements in our 2018 Form 10-K.

Note 2. Revenue Recognition

On October 1, 2018, we adopted ASC 606 using the modified retrospective method for contracts that were not completed as of the adoption date. The cumulative effect of initially applying ASC 606 was an adjustment to decrease the opening balance of Retained earnings by \$4.9 million, which is net of a \$4.8 million tax effect, as of October 1, 2018. Prior period amounts are not adjusted and continue to be reported in accordance with our historical revenue recognition policies.

Consistent with prior practice, revenue is presented in the Condensed Consolidated Statements of Income net of sales discounts and allowances, GPO fees, price concessions, rebates and customer returns for product sales and rental revenue reserves.

Prior to our adoption of ASC 606, we recognized revenue when the following criteria were met: evidence of an arrangement existed; delivery had occurred; the selling price was fixed or determinable and collection was considered probable. Following our adoption of ASC 606, we recognize revenue when we satisfy a performance obligation by transferring a promised good or service to a customer, as defined by the customer contract.

We elected to use the significant financing practical expedient under which the impacts of financing are considered immaterial if the duration of the financing is one year or less.

Customer payments are due at various times up to 90 days from the date of invoice, though in some countries and for certain customer types, credit terms are longer based on local industry practices.

Revenue related to certain products within our Patient Support Systems segment is required to be recognized later under ASC 606 than it was historically due to the determination that the performance obligation was a fully installed system. Historically, this obligation was accounted for as a multiple element arrangement and revenue was recognized upon delivery of hardware and software and the remainder when installation was complete. As a result of the deferral of the recognition of revenue, adoption date adjustments were required to be recorded related to deferred contract costs and equipment and other costs, which is reported in Other current assets and Other assets. Additionally, cash received from customers at inception of open contracts or billing that preceded satisfaction of remaining performance obligations is recorded as Deferred revenue in Other current liabilities and Other long-term liabilities.

Revenue related to certain products within our Front Line Care segment is required to be accelerated under ASC 606 compared to historical practice. This outcome is attributable to the conclusion that we have no on-going performance obligation after delivery of the product to the customer, whereas previously this revenue was recognized over the period the Company was reimbursed by third parties. As a result of the accelerated recognition of revenue, adoption date adjustments were required to be recorded to Trade accounts receivable, net of allowances and to derecognize assets previously recorded.

The cumulative effect of the changes made on the Condensed Consolidated Balance Sheets at October 1, 2018 for the adoption of ASC 606, is as follows:

Table of Contents

Impacted Condensed Consolidated Balance Sheet Items	September 30, 2018	Impacts of ASC 606	October 1, 2018
	As Reported	Adoption	After Adoption
ASSETS			
Trade accounts receivable, net of allowances	\$ 580.7	\$ 29.1	\$ 609.8
Other current assets	100.2	21.8	122.0
Property, plant and equipment, net	328.3	(5.6)	322.7
Deferred income taxes	35.0	5.6	40.6
Other assets	75.1	3.4	78.5
LIABILITIES			
Deferred revenue	40.0	47.5	87.5
Other current liabilities	67.1	0.8	67.9
Other long-term liabilities	40.4	10.9	51.3
SHAREHOLDERS' EQUITY			
Retained earnings	1,876.2	(4.9)	1,871.3

The impacts of ASC 606 in the quarter and year to date periods ended March 31, 2019 on our Condensed Consolidated Statement of Income are shown below.

Impacted Condensed Consolidated Statement of Income Items	Quarter Ended March 31, 2019			Year to Date Ended March 31, 2019		
	As Reported	Impacts of ASC 606	Balances without ASC 606	As Reported	Impacts of ASC 606	Balances without ASC 606
Product sales and service net revenue ¹	\$636.5	\$ 28.1	\$ 608.4	\$1,248.1	\$ 52.1	\$1,196.0
Rental net revenue ¹	77.7	(24.4)	102.1	149.6	(49.1)	198.7
Cost of goods sold ²	322.7	5.8	316.9	639.0	11.2	627.8
Rental expenses ²	38.9	(5.3)	44.2	76.1	(10.9)	87.0
Income tax expense (benefit)	11.2	0.5	10.7	18.6	0.4	18.2
Net income	49.5	2.7	46.8	91.7	2.3	89.4

¹ Includes \$23.3 million and \$47.5 million related to revenue previously classified as Rental revenue that has been reclassified to Product sales and service revenue as a result of the adoption of ASC 606 for the quarter and year to date periods ended March 31, 2019.

² Includes \$5.4 million and \$10.5 million related to cost of goods sold previously classified as Rental expenses that has been reclassified to Cost of goods sold as a result of the adoption of ASC 606 for the quarter and year to date periods ended March 31, 2019.

Within our Patient Support Systems segment, the adoption of ASC 606 impacted equipment and other costs which is reported in Other current assets and Other assets and deferred revenue which is reported in Other long-term liabilities.

Within our Front Line Care segment, the adoption of ASC 606 impacted the reported amount in Trade accounts receivable, net of allowances and results in the derecognition of assets previously recorded.

The impacts of the adoption of ASC 606 as of March 31, 2019, including the cumulative effects of the change, on our Condensed Consolidated Balance Sheet are shown below.

Table of Contents

Impacted Condensed Consolidated Balance Sheet Items	March 31, 2019		
	As Reported	Impacts of ASC 606	Balances without ASC 606
ASSETS			
Trade accounts receivable, net of allowances	\$581.8	\$ 30.7	\$ 551.1
Other current assets	118.4	17.2	101.2
Property, plant and equipment, net	313.3	(6.1)	319.4
Deferred income taxes	34.0	5.6	28.4
Other assets	94.4	3.4	91.0
LIABILITIES			
Deferred revenue	81.7	41.6	40.1
Other current liabilities	65.4	0.7	64.7
Other long-term liabilities	73.2	10.8	62.4
SHAREHOLDERS' EQUITY			
Retained earnings	1,935.2	(4.9)	1,940.1

Included in other current assets and other assets is equipment and other costs directly related to performance obligations that have not been completed for certain contracts in our Patient Support Systems segment. These costs are subsequently expensed to Cost of goods sold commensurate with the timing of the recognition of revenue, which is generally 12 to 24 months. As of March 31, 2019, we had \$15.2 million of equipment and other costs recorded within Other current assets and \$3.4 million in Other assets.

Deferred Contract Costs

Consistent with prior practice, deferred contract costs consist of commissions paid on receipt of a purchase order for certain products in our Patient Support Systems segment. These costs are subsequently expensed to Selling and administrative expenses commensurate with the timing of the recognition of revenue, which is generally 12 to 24 months. As of March 31, 2019, we had \$7.6 million of deferred contract costs recorded within Other current assets and Other assets. For the quarter and year to date periods ended March 31, 2019, we amortized \$3.1 million and \$6.5 million of deferred contract costs, which are classified within Selling and administrative expenses in the Condensed Consolidated Statements of Income.

Disaggregation of Revenue

The impact of the adoption of ASC 606 on the quarter and year to date periods ended March 31, 2019 is provided below.

Revenue related to certain products within our Patient Support Systems segment is required to be recognized later under ASC 606 than it was historically due to the determination that the performance obligation was a fully installed system. Historically, this obligation was accounted for as a multiple element arrangement and revenue was recognized upon delivery of hardware and software and the remainder when installation was complete.

Revenue related to certain products within our Front Line Care segment is required to be accelerated under ASC 606 compared to historical practice. This outcome is attributable to the conclusion that we do not have an on-going performance obligation after delivery of the product to the customer, whereas previously this revenue was recognized over the period the Company was reimbursed by third parties.

Table of Contents

	Quarter Ended March 31, 2019			Year to Date Ended March 31, 2019		
	As Reported	Impacts of ASC 606	Balances without ASC 606	As Reported	Impacts of ASC 606	Balances without ASC 606
Net revenue - United States:						
Patient Support Systems	\$267.2	\$ 2.4	\$ 264.8	\$515.3	\$ 1.0	\$514.3
Front Line Care	170.2	1.1	169.1	336.7	1.6	335.1
Surgical Solutions	55.6	—	55.6	109.5	—	109.5
Total net revenue - United States	\$493.0	\$ 3.5	\$ 489.5	\$961.5	\$ 2.6	\$958.9
Net revenue - Outside of the United States ("OUS"):						
Patient Support Systems	\$92.4	\$ 0.2	\$ 92.2	\$185.3	\$ 0.4	\$184.9
Front Line Care	72.9	—	72.9	139.8	—	139.8
Surgical Solutions	55.9	—	55.9	111.1	—	111.1
Total net revenue - OUS	\$221.2	\$ 0.2	\$ 221.0	\$436.2	\$ 0.4	\$435.8
Net revenue:						
Patient Support Systems	\$359.6	\$ 2.6	\$ 357.0	\$700.6	\$ 1.4	\$699.2
Front Line Care	243.1	1.1	242.0	476.5	1.6	474.9
Surgical Solutions	111.5	—	111.5	220.6	—	220.6
Total net revenue	\$714.2	\$ 3.7	\$ 710.5	\$1,397.7	\$ 3.0	\$1,394.7

Contract Balances

The nature of our products and services does not give rise to contract assets as we typically do not have instances where a right to payment for goods and services already transferred to a customer exists that is conditional on something other than the passage of time.

The following summarizes contract liability activity during the year to date period ended March 31, 2019. The contract liability balance as of March 31, 2019 represents the transaction price allocated to the remaining performance obligations.

	Contract Liabilities
Balance as of September 30, 2018	\$ 47.8
Revenue deferred due to ASC 606 initial adoption	58.4
New revenue deferrals	114.3
Revenue recognized upon satisfaction of performance obligations	(117.8)
Balance as of March 31, 2019	\$ 102.7

We expect to satisfy the majority of the remaining performance obligations related to installation and recognize the associated revenue in approximately 12 months. We expect to satisfy the majority of the remaining performance obligations related to service contracts and recognize the associated revenue generally within 24 months.

Table of Contents**Note 3. Supplementary Balance Sheet Information**

	March 31, 2019	September 30, 2018
Allowance for possible losses and discounts on trade receivables	\$ 22.1	\$ 21.8
Inventories, net of reserves:		
Finished products	\$ 142.7	\$ 139.7
Raw materials and work in process	151.1	152.0
Total inventories, net of reserves	\$ 293.8	\$ 291.7
Accumulated depreciation of property, plant and equipment	\$ 578.2	\$ 586.7
Accumulated amortization of software and other intangible assets	\$ 587.3	\$ 532.8
Investments included in Other assets	\$ 50.8	\$ 24.6
Preferred stock, without par value:		
Shares authorized	1,000,000	1,000,000
Shares issued	None	None
Common stock, without par value:		
Shares authorized	199,000,000	199,000,000
Shares issued	88,457,634	88,457,634
Shares outstanding	66,771,727	67,256,112
Treasury shares	21,685,907	21,201,522

Investments

In the first quarter of fiscal 2019, we acquired \$26.6 million of non-marketable equity securities that are valued at cost. There has not been any impairment of the historical cost of our investments in non-marketable equity securities.

Note 4. Business Combinations**Acquisition**

On April 1, 2019, we completed the acquisition of Voalte, Inc. ("Voalte"), a clinical communications software company, for consideration of \$180.0 million, subject to certain post-closing adjustments that may change the purchase price, and committed to up to an additional earnout payments related to the achievement of certain commercial milestones. We paid \$178.1 million on April 1, 2019, which consisted of the consideration of \$180.0 million plus cash acquired of \$9.6 million, less debt assumed of \$9.0 million and favorable working capital of \$2.5 million. The transaction was financed through borrowings on our revolving credit facility. It is not practicable to disclose the preliminary purchase price allocation for this transaction given the short period of time between the acquisition date and the filing of this Report.

Asset Acquisition

On October 1, 2018, we acquired the right to use patented technology and certain related assets from a supplier to our Front Line Care segment. We paid \$17.1 million of cash and committed to guaranteed minimum future royalty payments of \$22.0 million which are presented in Other intangible assets and software, net and are being amortized over the 7-year term of the agreement.

Dispositions

17

Table of Contents

In fiscal 2017, we sold our Völker business. In the first quarter of fiscal 2018, we recorded a gain of \$1.0 million attributable to the final working capital settlement associated with the Völker transaction.

During the second quarter of fiscal 2018, we entered into an agreement to convey certain net assets related to the Company's third-party rental business, which is comprised of purchased moveable medical equipment that can be rented to customers, to Universal Hospital Services, Inc. ("UHS") in exchange for UHS's agreement to dismiss its previously disclosed litigation against the Company ("Settlement Agreement"). We recorded a loss of \$23.4 million in Special charges, which includes approximately \$20.4 million related to the non-cash loss reserve for the assets to be conveyed, and other Settlement Agreement related costs of approximately \$3.0 million. The third-party rental business was part of our Patient Support Systems segment. The transaction closed during the third quarter of fiscal 2018.

Note 5. Goodwill

The following summarizes goodwill activity by reportable segment:

	Patient Support Systems	Front Line Care	Surgical Solutions	Total
Balances as of September 30, 2018				
Goodwill	\$ 544.4	\$ 1,370.6	\$ 296.1	\$ 2,211.1
Accumulated impairment losses	(472.8)	—	—	(472.8)
Goodwill, net as of September 30, 2018	71.6	1,370.6	296.1	1,738.3
Changes in Goodwill in the period:				
Currency translation effect	(1.0)	(2.6)	(1.8)	(5.4)
Balances as of March 31, 2019				
Goodwill	543.4	1,368.0	294.3	2,205.7
Accumulated impairment losses	(472.8)	—	—	(472.8)
Goodwill, net as of March 31, 2019	\$ 70.6	\$ 1,368.0	\$ 294.3	\$ 1,732.9

Note 6. Financing Agreements

Total debt consists of the following:

	March 31, 2019	September 30, 2018
Current portion of long-term debt	\$ 33.2	\$ 0.1
Securitization Program	110.0	110.0
Note Securitization Facility	81.5	72.4
Total Short-term borrowings	\$ 224.7	\$ 182.5
Revolving credit facility, matures September 2021	\$ 5.0	\$ —
Senior secured Term Loan A, long-term portion, matures September 2021	998.1	1,029.7
Senior unsecured 5.75% notes due on September 1, 2023	421.2	420.8
Senior unsecured 5.00% notes due on February 15, 2025	296.7	296.4
Unsecured 7.00% debentures due on February 15, 2024	13.5	13.6
Unsecured 6.75% debentures due on December 15, 2027	29.6	29.5
Other	0.3	0.4
Total Long-term debt	\$ 1,764.4	\$ 1,790.4

Total debt	\$ 1,989.1	\$ 1,972.9
------------	-------------------	------------

18

Table of Contents

In May 2018, we renewed our 364-day accounts receivable securitization program (the “Securitization Program”) with certain financial institutions for borrowings up to \$110.0 million. We also entered into an additional 364-day facility for borrowings up to \$90.0 million (the “Note Securitization Facility”) in May 2018. Under the terms of each of the Securitization Program and Note Securitization Facility, certain of our accounts receivable secure the amounts borrowed and cannot be used to pay our other debts or liabilities. The amount that we may borrow at a given point in time is determined based on the amount of qualifying accounts receivable that are present at such point in time. Borrowings outstanding under the Securitization Program and Note Securitization Facility bear interest at the London Interbank Offered Rate (“LIBOR”) plus the applicable margin of 0.8% and 1.0% and are included as a component of Short-term borrowings, while the accounts receivable securing these obligations remain as a component of Trade accounts receivable, net of allowances, in our Condensed Consolidated Balance Sheets. In addition, the agreements governing the Securitization Program and Note Securitization Facility contain various customary affirmative and negative covenants, and customary default and termination provisions. As of March 31, 2019, we were in compliance with these covenants and provisions.

We have outstanding senior unsecured notes of \$300.0 million maturing February 2025 that bear interest at a fixed rate of 5.00% annually, and senior unsecured notes of \$425.0 million maturing in September 2023 that bear interest at a fixed rate of 5.75% annually (collectively, the “Senior Notes”). These Senior Notes were issued at par in private placement offerings and are not registered securities on any public market. All of the notes were outstanding as of March 31, 2019. We are not required to make any mandatory redemption or sinking fund payments with respect to the Senior Notes, other than in certain circumstances such as a change in control or material sale of assets. We may redeem the 5.00% and 5.75% notes prior to maturity, but doing so prior to February 15, 2025 and September 1, 2023, respectively, would require payment of a premium on any amounts redeemed, the amount of which varies based on the timing of the redemption. The indentures governing the Senior Notes contain certain covenants which impose limitations on the amount of dividends we may pay and the amount of common shares we may repurchase in the open market, but we do not expect these covenants to affect our current dividend policy or open share repurchase program. The terms of these indentures also impose certain restrictions on the amount and type of additional indebtedness we may obtain in the future, as well as the types of liens and guarantees we may provide.

Our Senior Credit Agreement consists of two facilities as follows:

\$1,462.5 million senior secured Term Loan A facility (“TLA Facility”), maturing in September 2021

Revolving Credit Facility providing borrowing capacity of up to \$700.0 million, maturing in September 2021

The TLA Facility and Revolving Credit Facility bear interest at variable rates which currently approximate 4.0%. These interest rates are based primarily on LIBOR, but under certain conditions could also be based on the U.S. Federal Funds Rate or the U.S. Prime Rate, at our option. We are able to voluntarily prepay outstanding loans under the TLA Facility at any time. In the quarter ended March 31, 2019, we did not make any payments on the TLA Facility.

As of March 31, 2019, there were outstanding borrowings of \$5.0 million on the Revolving Credit Facility, and available borrowing capacity was \$687.0 million after giving effect to \$8.0 million of outstanding standby letters of credit. The availability of borrowings under our Revolving Credit Facility is subject to our ability at the time of borrowing to meet certain specified conditions, including compliance with covenants contained in the Senior Credit Agreement.

The facilities provided by the Senior Credit Agreement are held with a syndicate of banks, which includes over 30 institutions. Our general corporate assets, including those of certain of our subsidiaries, collateralize these obligations. The credit agreement governing these facilities contains financial covenants which specify a maximum secured net leverage ratio and a minimum interest coverage ratio, as such terms are defined in the credit agreement. These financial covenants are measured at the end of each quarter. For any quarter ended in December 31, 2019 and

thereafter, the required maximum secured net leverage ratio is 3.00x and the required minimum interest coverage ratio is 4.00x. We were in compliance with all financial covenants under our financing agreements as of March 31, 2019.

The fair value of our debt is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to us for debt of the same remaining maturities. The book values of our variable rate short-term debt instruments and Revolving Credit Facility approximate fair value.

Table of Contents

The estimated fair values of our long-term debt instruments are described in the table below:

	March 31,	September 30,
	2019	2018
Senior secured Term Loan A	\$ 999.5	\$ 991.9
Senior unsecured 5.75% notes due on September 1, 2023	438.6	437.3
Senior unsecured 5.00% notes due on February 14, 2025	305.3	294.0
Unsecured debentures	44.1	42.9
Total	\$ 1,787.5	\$ 1,766.1

The estimated fair values of our long-term unsecured debentures were based on observable inputs such as quoted prices in markets that are not active. The estimated fair values of our term loans and the Senior Notes were based on quoted prices for similar liabilities. These fair value measurements are classified as Level 2, as described in Note 1.

Derivatives and Hedging Activities

Cash Flow Hedges

We are exposed to market risk from fluctuations in interest rates. We sometimes manage our exposure to interest rate fluctuations through the use of interest rate swaps. As of March 31, 2019, we had five interest rate swap agreements, with an aggregate notional amount of \$750.0 million to hedge the variability of cash flows associated with a portion of the variable interest rate payments through September 2021 on the Senior Credit Agreement. The interest rate swaps have effective start dates ranging between December 31, 2018 and September 8, 2020 and were designated as cash flow hedges. As of March 31, 2019 and September 30, 2018, these swaps were in a net asset position with an aggregate fair value of \$6.8 million and \$24.8 million, all of which were classified as Other assets. We classify fair value measurements on our interest rate swaps as Level 2, as described in Note 1.

We are subject to variability in foreign currency exchange rates due to our international operations. Exposure to this variability is periodically managed primarily through the use of natural hedges, whereby funding obligations and assets are both managed in the local currency. From time-to-time, we enter into currency exchange agreements to manage our exposure arising from fluctuating exchange rates related to specific and projected transactions. We operate this program pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. The sensitivity of earnings and cash flows to variability in exchange rates is assessed by applying an appropriate range of potential rate fluctuations to our assets, obligations and projected results of operations denominated in foreign currencies. Our currency risk consists primarily of foreign currency denominated firm commitments and projected foreign currency denominated intercompany and third-party transactions. As of March 31, 2019, the notional amount of open foreign exchange contracts was \$39.7 million. These contracts were in a net asset position reported in Other current assets with a fair value of \$0.5 million. The maximum length of time over which we hedge transaction exposures is generally 15 months. Derivative gains and losses, initially reported as a component of Accumulated other comprehensive income (loss), are reclassified to earnings in the period when the transaction affects earnings.

Net Investment Hedges

In July 2018, we entered into two cross-currency swap agreements, with an aggregate notional amount of \$198.7 million to hedge the variability of U.S. dollar-Euro exchange rates through July 2023. These cross-currency swaps are designated as net investment hedges of subsidiaries using Euro as their functional currency. We entered into these cross-currency swaps to mitigate changes in net assets due to changes in U.S. dollar-Euro spot exchange rates. As of March 31, 2019, these swaps were in a net asset position with an aggregate fair value of \$9.2 million which was

classified as Other assets. As of September 30, 2018, these swaps were in a net liability position with an aggregate fair value of \$1.2 million which was classified as Other current liabilities.

We classify fair value measurements on our cross-currency swaps as Level 2, as described in Note 1. We assess hedge effectiveness under the spot-to-spot method and record changes in fair value attributable to the translation of foreign currencies through Accumulated other comprehensive income (loss). We amortize the impact of all other changes in fair value of the derivative through Interest expense, which was income of \$1.2 million and expense of \$0.1 million for the quarter and year to date periods ended March 31, 2019.

Undesignated Derivative Instruments

Table of Contents

We use forward contracts to mitigate the foreign exchange revaluation risk associated with recorded monetary assets and liabilities that are denominated in a non-functional currency. These derivative instruments are not formally designated as hedges and the terms of these instruments generally do not exceed one month. As of March 31, 2019, we had forward contracts not designated as hedges with an aggregate notional amount of \$74.8 million. During the quarter and year to date periods ended March 31, 2019, we recognized unrealized losses of \$0.5 million and losses of \$0.3 million in Investment income and other, net related to these forward contracts not designated as hedges.

Note 7. Retirement and Postretirement Plans

We sponsor five defined benefit retirement plans. Those plans include a master defined benefit retirement plan in the United States, a nonqualified supplemental executive defined benefit retirement plan, and three defined benefit retirement plans covering employees in Germany and France. Benefits for such plans are based primarily on years of service and the employee's level of compensation in specific periods of employment. We contribute funds to trusts as necessary to provide for current service and for any unfunded projected future benefit obligation over a reasonable period of time. All of our plans have a September 30 measurement date. The following table details the components of net pension expense for our defined benefit retirement plans.

	Quarter Ended		Year to Date Ended		Condensed Consolidated Statements of Income Item
	March 31 2019	March 31 2018	March 31 2019	March 31 2018	
Service cost	\$0.4	\$0.3	\$0.7	\$0.7	Cost of goods sold
Service cost	0.7	0.9	1.5	1.7	Selling and administrative expenses
Interest cost	3.2	2.8	6.3	5.5	Investment income and other, net
Expected return on plan assets	(3.7)	(4.0)	(7.4)	(7.9)	Investment income and other, net
Amortization of net loss	0.6	1.0	1.2	2.2	Investment income and other, net
Net pension expense	\$1.2	\$1.0	\$2.3	\$2.2	

In addition to defined benefit retirement plans, we also offer two postretirement health care plans in the United States that provide health care benefits to qualified retirees and their dependents. The plans are closed to new participants and include retiree cost sharing provisions and generally extends retiree coverage for medical and prescription benefits beyond the COBRA continuation period to the date of Medicare eligibility. Annual costs related to these plans are not significant.

We have defined contribution savings plans that cover substantially all U.S. employees and certain non-U.S. employees. The general purpose of these plans is to provide additional financial security in retirement by providing employees with an incentive to make regular savings. Our contributions to the plans are based on eligibility and, in some cases, employee contributions. Expense under these plans was \$8.3 million and \$7.5 million in each of the quarterly periods ended March 31, 2019 and 2018. Expense under these plans was \$14.5 million and \$13.9 million in the year to date periods ended March 31, 2019 and 2018.

Table of Contents**Note 8. Other Comprehensive Income (Loss)**

The following table represents the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the quarter ended March 31, 2019:

	Quarter Ended March 31, 2019					Accumulated other comprehensive income (loss)		
	Other comprehensive income (loss)					Beginning balance	Net activity	Ending balance ²
	Prior to reclassification	Reclassification from	Pre-tax	Tax effect	Net of tax			
Derivative instruments designated as hedges ¹ :								
Foreign exchange forward contracts	\$(0.7)	\$ (0.1)	\$(0.8)	\$0.3	\$(0.5)	\$0.9	\$(0.5)	\$0.4
Interest rate swaps	(9.1)	(1.7)	(10.8)	2.3	(8.5)	13.8	(8.5)	5.3
Cross-currency swaps	8.1	—	8.1	(1.0)	7.1	(0.8)	7.1	6.3
Derivative instruments designated as hedges total	(1.7)	(1.8)	(3.5)	1.6	(1.9)	13.9	(1.9)	12.0
Foreign currency translation adjustment	(3.6)	—	(3.6)	—	(3.6)	(118.9)	(3.6)	(122.5)
Change in pension and postretirement defined benefit plans	0.1	0.6	0.7	(0.2)	0.5	(30.3)	0.5	(29.8)
Total	\$(5.2)	\$ (1.2)	\$(6.4)	\$1.4	\$(5.0)	\$(135.3)	\$(5.0)	\$(140.3)

¹ See Note 6 for information regarding our hedging strategies.

² The estimated net amount of gains and losses that are reported in Accumulated other comprehensive income (loss) related to our derivative instruments designated as hedges as of March 31, 2019 that is expected to be reclassified into earnings within the next 12 months is \$4.0 million.

The following table represents the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the quarter ended March 31, 2018:

	Quarter Ended March 31, 2018					Accumulated other comprehensive income (loss)		
	Other comprehensive income (loss)					Beginning balance	Net activity	Ending balance
	Prior to reclassification	Reclassification from	Pre-tax	Tax effect	Net of tax			
Derivative instruments designated as hedges:								
Foreign exchange forward contracts	\$0.4	\$ 0.4	\$0.8	\$(0.2)	\$0.6	\$(0.8)	\$0.6	\$(0.2)
Interest rate swaps	9.3	(0.9)	8.4	(1.1)	7.3	8.5	7.3	15.8
Derivative instruments designated as hedges total	9.7	(0.5)	9.2	(1.3)	7.9	7.7	7.9	15.6
Foreign currency translation adjustment	16.5	—	16.5	—	16.5	(75.2)	16.5	(58.7)
Change in pension and postretirement defined benefit plans	(0.1)	1.0	0.9	(0.1)	0.8	(32.2)	0.8	(31.4)
Total	\$26.1	\$ 0.5	\$26.6	\$(1.4)	\$25.2	\$(99.7)	\$25.2	\$(74.5)

Table of Contents

The following table represents the changes in Other comprehensive income (loss) by component for the year to date period ended March 31, 2019:

	Year to Date Ended March 31, 2019				
	Other comprehensive income (loss)				
	Prior to reclassification	Reclassification from	Pre-tax	Tax effect	Net of tax
Derivative instruments designated as hedges:					
Foreign exchange forward contracts	\$0.5	\$ (0.2)	\$0.3	\$(0.1)	\$0.2
Interest rate swaps	(14.2)	(3.8)	(18.0)	4.2	(13.8)
Cross-currency swaps	10.3	—	10.3	(2.3)	8.0
Derivative instruments designated as hedges total	(3.4)	(4.0)	(7.4)	1.8	(5.6)
Foreign currency translation adjustment	(17.2)	—	(17.2)	—	(17.2)
Change in pension and postretirement defined benefit plans	0.1	1.1	1.2	(0.3)	0.9
Total	\$(20.5)	\$ (2.9)	\$(23.4)	\$1.5	\$(21.9)

The following table represents the changes in Accumulated other comprehensive income (loss) by component for the year to date period ended March 31, 2019:

	Accumulated other comprehensive income (loss)			
	Balances as of September 30, 2018	Impacts of ASU 2018-02 Adoption as of October 1, 2018	Net activity for Year to Date Ended March 31, 2019	Balances as of March 31, 2019
Derivative instruments designated as hedges:				
Foreign exchange forward contracts	\$0.2	\$ —	\$0.2	\$0.4
Interest rate swaps	18.3	0.8	(13.8)	5.3
Cross-currency swaps	(1.7)	—	8.0	6.3
Derivative instruments designated as hedges total	16.8	0.8	(5.6)	12.0
Foreign currency translation adjustment	(105.3)	—	(17.2)	(122.5)
Change in pension and postretirement defined benefit plans	(24.5)	(6.2)	0.9	(29.8)
Total	\$(113.0)	\$ (5.4)	\$(21.9)	\$(140.3)

Table of Contents

The following table represents the changes in Other comprehensive income (loss) and Accumulated other comprehensive income (loss) by component for the year to date period ended March 31, 2018:

	Year to Date Ended March 31, 2018					Accumulated other comprehensive income (loss)		
	Prior to reclassification	Reclassification from	Pre-tax	Tax effect	Net of tax	Beginning balance	Net activity	Ending balance
Derivative instruments designated as hedges:								
Foreign exchange forward contracts	\$(0.5)	\$ 0.8	\$ 0.3	\$(0.1)	\$0.2	\$(0.4)	\$ 0.2	\$(0.2)
Interest rate swaps	16.0	(1.7)	14.3	(3.2)	11.1	4.7	11.1	15.8
Derivative instruments designated as hedges total	15.5	(0.9)	14.6	(3.3)	11.3	4.3	11.3	15.6
Foreign currency translation adjustment	22.6	—	22.6	—	22.6	(81.3)	22.6	(58.7)
Change in pension and postretirement defined benefit plans	(0.2)	2.2	2.0	(0.4)	1.6	(33.0)	1.6	(31.4)
Total	\$37.9	\$ 1.3	\$ 39.2	\$(3.7)	\$35.5	\$(110.0)	\$ 35.5	\$(74.5)

The following table represents the items reclassified out of Accumulated other comprehensive income (loss) and the related tax effects for the quarters ended March 31, 2019 and 2018:

	Quarter Ended March 31		Net of tax	Amount reclassified	Tax effect	Net of tax
	2019	2018				
Derivative instruments designated as hedges:						
Foreign exchange forward contracts ¹	\$(0.1)	\$(0.1)	\$(0.2)	\$0.4	\$ —	\$0.4
Interest rate swaps ²	(1.7)	0.5	(1.2)	(0.9)	—	(0.9)
Derivative instruments designated as hedges total	(1.8)	0.4	(1.4)	(0.5)	—	(0.5)
Change in pension and postretirement defined benefit plans ³	0.6	(0.2)	0.4	1.0	(0.1)	0.9

The following table represents the items reclassified out of Accumulated other comprehensive income (loss) and the related tax effects for the year to date periods ended March 31, 2019 and 2018:

Table of Contents

	Year to Date Ended March 31					
	2019		2018			
	Amount	Tax	Net of	Amount	Tax	Net
	reclassified ⁴	effect ⁴	tax	reclassified	effect	of tax
Derivative instruments designated as hedges:						
Foreign exchange forward contracts ¹	\$ (0.2)	\$ —	\$ (0.2)	\$ 0.8	\$ (0.1)	\$ 0.7
Interest rate swaps ²	(3.8)	1.1	(2.7)	(1.7)	0.3	(1.4)
Derivative instruments designated as hedges total	(4.0)	1.1	(2.9)	(0.9)	0.2	(0.7)
Change in pension and postretirement defined benefit plans ³	1.1	(6.5)	(5.4)	2.2	(0.4)	1.8

¹ Reclassified from Accumulated other comprehensive income (loss) into Investment income and other, net.

² Reclassified from Accumulated other comprehensive income (loss) into Interest expense.

³ Reclassified from Accumulated other comprehensive income (loss) into Cost of goods sold, Selling and administrative expenses and Investment income and other, net. These components are included in the computation of net periodic pension expense.

⁴ As a result of the adoption of ASU 2018-02, we reclassified \$5.4 million from Accumulated other comprehensive income (loss) to Retained earnings.

Note 9. Special Charges

In connection with various organizational changes to improve our business alignment and cost structure, we recognized Special charges of \$3.5 million and \$36.9 million for the quarters ended March 31, 2019 and 2018 and \$11.5 million and \$50.4 million for the year to date periods ended March 31, 2019 and 2018. We continue to evaluate additional actions related to these programs and expect additional Special charges to be incurred. However, it is not practicable to estimate the amount of these future expected costs until such time as the evaluations are complete.

These charges are summarized as follows:

Disposition

During the second quarter of fiscal 2018, we entered into an agreement to convey certain assets related to the Company's third-party rental business to UHS and recorded an after-tax loss of \$23.4 million in Special charges.

Business Optimization

In fiscal 2018, we initiated a global transformation program focused on reducing complexity, increasing efficiency, improving our cost structure with targeted investments that align with our strategic priorities. For the quarter and year to date periods ended March 31, 2019, this program resulted in charges of \$2.5 million and \$6.3 million, of which \$1.0 million and \$3.8 million were severance and benefit costs with the remainder related to professional fees and project management costs. These amounts compare to charges of \$9.6 million and \$18.8 million in the quarter and year to date periods ended March 31, 2018, of which \$4.8 million and \$10.8 million were severance and benefit costs.

Site Consolidation

We continue to streamline our operations and simplify our supply chain by consolidating certain manufacturing and distribution operations ("Site Consolidation"). Since the inception of this program, we have announced the closure of nine sites. In the quarter and year to date periods ended March 31, 2019, we recorded charges of \$1.0 million and \$5.1 million related to these efforts, of which \$0.7 million were severance and benefit costs for the quarter and year to date periods ending March 31, 2019. The remaining costs primarily consisted of lease termination and facility closure costs. These amounts compare to charges of \$3.8 million and \$7.8 million in the quarter and year to date periods

ended March 31, 2018, of which \$0.5 million and \$0.7 million were severance and benefit costs.

Since the inception of the Site Consolidation program through March 31, 2019, we have recognized aggregate Special charges of \$55.9 million.

25

Table of Contents*Integration and Business Realignment*

As we acquire businesses, we initiate integration activities and position our existing businesses to capitalize on opportunities for growth. We also incur costs, including severance and benefit costs, associated with other business realignment and integration activities. In the year to date period ended March 31, 2019, we incurred integration and business realignment charges of approximately \$0.1 million. We incurred no integration and business realignment charges in the quarter ended March 31, 2019. These amounts compare to charges of \$0.1 million and \$0.4 million in the quarter and year to date periods ended March 31, 2018.

For all accrued severance and other benefit charges described above, we record restructuring reserves within Other current liabilities. The reserve activity for severance and other benefits in the year to date period ended March 31, 2019 was as follows:

Balance as of September 30, 2018	\$8.5
Expenses	6.1
Cash Payments	(8.1)
Reversals	(1.2)
Balance as of March 31, 2019	\$5.3

Note 10. Income Taxes

The effective tax rate for the quarter ended March 31, 2019 was 18.5% compared to (32.6)% for the comparable period in the prior year due primarily to the difference in the discrete tax benefits realized in each period. The current period rate was favorably impacted by \$1.4 million of discrete tax benefits primarily related to excess tax benefits on deductible stock compensation. This compares to \$11.2 million of discrete tax benefits in the comparable prior year period which primarily related to a change in tax accounting method for historical currency losses.

The effective tax rate for the year to date period ended March 31, 2019 was 16.9% compared to (123.3)% for the comparable period in the prior year due primarily to tax benefits recorded in the prior period related to the Tax Act. The year to date period rate was favorably impacted by \$4.5 million of discrete tax benefits primarily related to \$2.4 million of excess tax benefits on deductible stock compensation. This compares to \$75.6 million of discrete tax benefits in the prior year to date period primarily related to the Tax Act and a change in tax accounting method for historical currency losses.

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Act. The Tax Act made broad and complex changes to the U.S. tax code which impacted the financial results of our fiscal year ended September 30, 2018, and continues to impact the financial results of the quarter and year to date periods ended March 31, 2019, including, but not limited to (1) reducing the U.S. Federal corporate tax rate, (2) requiring a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that may electively be paid over eight years, and (3) accelerated first year expensing of certain capital expenditures. The Tax Act reduced the U.S. Federal corporate tax rate from 35.0% to 21.0% effective January 1, 2018 for calendar year tax filers. In accordance with Internal Revenue Code Section 15, our fiscal year ended September 30, 2018 had a blended corporate tax rate of 24.5%, which was based on a proration of the applicable tax rates before and after the effective date of the Tax Act. The statutory tax rate of 21.0% applies to our current fiscal 2019.

The Tax Act also put in place new tax laws that will impact our taxable income in fiscal 2019, which include, but are not limited to (1) creating a Base Erosion Anti-abuse Tax (“BEAT”), which is a tax on certain related-party payments that reduce the U.S. tax base, (2) generally eliminating U.S. Federal income taxes on dividends from foreign

subsidiaries, (3) a new provision designed to tax currently global intangible low-taxed income (“GILTI”), which allows for the possibility of utilizing foreign tax credits and a deduction equal to 50.0% to offset the income tax liability (subject to some limitations), (4) a provision that could limit the amount of deductible interest expense, (5) the repeal of the domestic production activity deduction replaced with an additional deduction for foreign-derived intangible income (“FDII”), (6) limitations on the deductibility of certain executive compensation, and (7) limitations on the utilization of foreign tax credits to reduce the U.S. income tax liability.

Shortly after the Tax Act was enacted, the SEC staff issued Staff Accounting Bulletin No. 118, *Income Tax Accounting Implications of the Tax Cuts and Jobs Act* (“SAB 118”) which provides guidance on accounting for the Tax Act’s impact. SAB 118 provided a measurement period, which in no case should extend beyond one year from the Tax Act enactment date, during which a company acting in good faith may complete the accounting for the impacts of the Tax Act under ASC Topic 740. In accordance with the expiration of the SAB 118 measurement period, we completed the assessment of the income tax effects of the Tax Act in the first quarter of fiscal 2019 and further reduced our Transition Tax liability by \$1.0 million in the first quarter of fiscal 2019.

Table of Contents

The U.S. Internal Revenue Service and Treasury Department continue to release proposed guidance with respect to the Tax Act. We continue to evaluate what impact, if any, each piece of guidance may have on our related tax positions and our effective tax rate if, and when, such guidance is finalized.

Note 11. Earnings per Common Share

Basic earnings per share is calculated based upon the weighted average number of outstanding common shares for the period, plus the effect of deferred vested shares. Diluted earnings per share is calculated consistent with the basic earnings per share calculation plus the effect of dilutive unissued common shares related to stock-based employee compensation programs. For all periods presented, anti-dilutive stock options were excluded from the calculation of diluted earnings per share. Cumulative treasury stock acquired, less cumulative shares reissued, have been excluded in determining the average number of shares outstanding.

Earnings per share are calculated as follows (share information in thousands):

	Quarter Ended		Year to Date Ended	
	March 31		March 31	
	2019	2018	2019	2018
Net income	\$49.5	\$ 28.5	\$91.7	\$ 116.8
Average basic shares outstanding	66,696	66,192	66,866	66,040
Add potential effect of exercise of stock options and other unvested equity awards	648	1,405	659	1,468
Average diluted shares outstanding	67,344	67,597	67,525	67,508
Net income per basic common share	\$0.74	\$ 0.43	\$1.37	\$ 1.77
Net income per diluted common share	\$0.74	\$ 0.42	\$1.36	\$ 1.73
Shares with anti-dilutive effect excluded from the computation of diluted EPS	307	280	286	225

Note 12. Common Stock

The stock-based compensation cost that was charged against income for all plans was \$11.4 million and \$9.5 million in the quarterly periods ended March 31, 2019 and 2018. The stock-based compensation cost that was charged against income for all plans was \$16.9 million and \$15.8 million in the year to date periods ended March 31, 2019 and 2018.

In connection with employees satisfying payroll tax withholding obligations for restricted stock distributions, we purchased 43,135 shares of our common stock for \$4.0 million in the year to date period ended March 31, 2019, and 53,811 shares for \$4.4 million in the year to date period ended March 31, 2018.

We purchased 792,264 shares of our common stock in the open market under our share repurchase program for \$75.0 million in the year to date period ended March 31, 2019. We did not repurchase shares in the quarter ended March 31, 2019 in the open market.

As of March 31, 2019, a cumulative total of \$250.3 million of our share repurchase program had been used, leaving us with the ability to repurchase shares with a value of \$89.7 million. This program does not have an expiration date and there are no plans to terminate this program in the future.

Note 13. Guarantees

We routinely grant limited warranties on our products with respect to defects in material and workmanship. The terms of these warranties are generally one year, however, certain components and products have substantially longer warranty periods. We recognize a reserve with respect to these obligations at the time of product sale, with subsequent warranty claims recorded directly against the reserve. The amount of the warranty reserve is determined based on historical trend experience for the covered products. For more significant warranty-related matters which might require a broad-based correction, separate reserves are established when such events are identified and the cost of correction can be reasonably estimated.

27

Table of Contents

A rollforward of changes in the warranty reserve for the periods covered in this report is as follows:

	Quarter Ended		Year to Date Ended	
	March 31		March 31	
	2019	2018	2019	2018
Balance as of beginning of period	\$24.9	\$25.3	\$20.5	\$25.5
Provision for warranties in the period	4.1	4.0	9.2	7.5
Warranty reserves assumed ¹	—	—	2.8	—
Warranty claims in the period	(4.5)	(4.3)	(8.0)	(8.0)
Balance as of end of period	\$24.5	\$25.0	\$24.5	\$25.0

¹As a result of the asset acquisition discussed in Note 4.

In the normal course of business, we enter into various other guarantees and indemnities in our relationships with suppliers, service providers, customers, business partners and others. Examples of these arrangements would include guarantees of product performance, indemnifications to service providers and indemnifications of our actions to business partners. These guarantees and indemnifications have not historically had a material impact on our financial condition or results of operations, nor do we expect them to, although indemnifications associated with our actions generally have no dollar limitations.

In conjunction with our acquisition and divestiture activities, we have entered into select guarantees and indemnifications of performance with respect to the fulfillment of commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. With respect to sale transactions, we also routinely enter into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have a materially adverse impact on our financial condition and results of operations.

Note 14. Segment Reporting

We disclose segment information that is consistent with the way in which management operates and views the business. Our operating structure contains the following reporting segments:

Patient Support Systems – globally provides our med-surg and specialty bed systems and surfaces, safe patient handling equipment and mobility solutions, as well as our clinical workflow solutions that deliver software and information technologies to improve care and deliver actionable insight to caregivers and patients.

Front Line Care – globally provides patient monitoring and diagnostic technologies, including a diversified portfolio of physical assessment tools that help diagnose, treat and manage a wide variety of illnesses and diseases, as well as a portfolio of vision care and respiratory care devices.

Surgical Solutions – globally provides products that improve surgical safety and efficiency in the operating room including tables, lights, pendants, positioning devices and various other surgical instruments and accessories.

Our performance within each reportable segment continues to be measured on a divisional income basis before non-allocated operating and administrative costs, litigation, special charges, acquisition and integration costs, acquisition-related intangible asset amortization, and other unusual events. Divisional income generally represents the

division's gross profit less its direct operating costs along with an allocation of manufacturing and distribution costs, research and development and certain corporate functional expenses.

Table of Contents

Non-allocated operating costs, administrative costs, and other includes functional expenses that support the entire organization such as administration, finance, legal and human resources, expenses associated with strategic developments, acquisition-related intangible asset amortization, and other events that are not indicative of operating trends. We exclude such amounts from divisional income to allow management to evaluate and understand divisional operating trends. The chief operating decision maker does not receive any asset information by operating segment and, accordingly, we do not report asset information by operating segment.

	Quarter Ended		Year to Date Ended	
	March 31		March 31	
	2019	2018	2019	2018
Net revenue:				
Patient Support Systems	\$359.6	\$355.0	\$700.6	\$689.4
Front Line Care	243.1	237.9	476.5	462.5
Surgical Solutions	111.5	117.6	220.6	228.3
Total net revenue	\$714.2	\$710.5	\$1,397.7	\$1,380.2
Divisional income:				
Patient Support Systems	\$69.8	\$67.2	\$126.6	\$120.6
Front Line Care	67.1	60.5	127.0	115.9
Surgical Solutions	15.1	15.5	26.4	25.2
Other operating costs:				
Non-allocated operating costs, administrative costs, and other	67.2	60.2	116.4	113.1
Special charges	3.5	36.9	11.5	50.4
Operating profit	81.3	46.1	152.1	98.2
Interest expense	(21.8)	(24.2)	(43.1)	(47.3)
Investment income and other, net	1.2	(0.4)	1.3	1.4
Income before income taxes	\$60.7	\$21.5	\$110.3	\$52.3

Note 15. Commitments and ContingenciesGeneral

We are subject to various claims and contingencies arising out of the normal course of business, including those relating to governmental investigations and proceedings, commercial transactions, product liability, employee related matters, antitrust, safety, health, taxes, environmental and other matters. Litigation is subject to many uncertainties and the outcome of individual litigated matters is not predictable with assurance. It is possible that some litigation matters for which reserves have not been established could be decided unfavorably to us, and that any such unfavorable decisions could have a material adverse effect on our financial condition, results of operations, and cash flows.

Self Insurance

We are involved in various claims, including product and general liability, workers' compensation, auto liability and employment related matters. Such claims in the United States have deductibles and self-insured retentions at various limits up to \$1.0 million per occurrence or per claim, depending upon the type of coverage and policy period. International deductibles and self-insured retentions are lower. We are also generally self-insured up to certain stop-loss limits for certain employee health benefits, including medical, drug and dental. Our policy is to estimate

reserves based upon a number of factors including known claims, estimated incurred but not reported claims and outside actuarial analysis, which are based on historical information along with certain assumptions about future events. Such estimated reserves are classified as Other current liabilities and Other long-term liabilities within the Condensed Consolidated Balance Sheets.

Table of Contents

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements and Factors That May Affect Future Results

Certain statements in this Quarterly Report on Form 10-Q contain forward-looking statements within the meanings of the Private Securities Litigation Reform Act of 1995, as amended, regarding our future plans, objectives, beliefs, expectations, representations and projections.

Forward-looking statements are not guarantees of future performance, and our actual results could differ materially from those set forth in any forward-looking statements. For a more in-depth discussion of factors that could cause actual results to differ from forward-looking statements, see the discussions under the heading "Risk Factors" in our previously filed most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2018 ("2018 Form 10-K") as well as the discussions in this "Management's Discussion and Analysis of Financial Condition and Results of Operations." We assume no obligation to update or revise any forward-looking statements unless required by law.

Overview

The following discussion and analysis should be read in conjunction with the accompanying interim financial statements and our 2018 Form 10-K.

Hill-Rom Holdings, Inc. (the "Company," "Hill-Rom," "we," "us," or "our") was incorporated on August 7, 1969 in the State of Indiana and is headquartered in Chicago, Illinois. We are a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across multiple care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health. Our innovations ensure caregivers have the products they need to help diagnose, treat and protect their patients; speed up recoveries; and manage conditions. Every day, around the world, we enhance outcomes for patients and their caregivers.

Use of Non-GAAP Financial Measures

The accompanying Condensed Consolidated Financial Statements, including the related notes, are presented in accordance with accounting principles generally accepted in the United States ("GAAP"). In addition to the results reported in accordance with GAAP, we routinely provide gross margin, operating margin, income tax expense and earnings per diluted share results on an adjusted basis because we believe these measures contribute to an understanding of our financial performance, provide additional analytical tools to understand our results from core operations and reveal underlying operating trends. These measures exclude strategic developments, acquisition and integration costs, regulatory costs related to updating existing product registrations to comply with the European Medical Device Regulations, Special charges as described in Note 9 of our Condensed Consolidated Financial Statements in this Form 10-Q, the transitional impacts of the U.S. Tax Cuts and Jobs Act (the "Tax Act"), change in tax accounting methods, and other tax law changes as described in Note 10 of our Condensed Consolidated Financial Statements in this Form 10-Q, expenses associated with these tax items, the impacts of significant litigation matters or other unusual events. We also exclude expenses associated with the amortization of purchased intangible assets. These adjustments are made to allow investors to evaluate and understand operating trends excluding their impact on operating income and earnings per diluted share.

Management uses these measures internally for planning, forecasting and evaluating the performance of the business. Investors

should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP.

In addition, we present certain results on a constant currency basis, which compares results between periods as if foreign currency exchange rates had remained consistent period-over-period. We monitor sales performance on an adjusted basis that eliminates the positive or negative effects that result from translating international sales into U.S. dollars. We calculate constant currency by applying the foreign currency exchange rate for the prior period to the local currency results for the current period. We believe that evaluating growth in net revenue on a constant currency basis provides an additional and meaningful assessment to both management and investors.

Table of Contents**Results of Operations**

In this section, we provide an overview of our results of operations. We disclose segment information that is consistent with the way in which management operates and views the business. Our operating structure contains the following reporting segments:

Patient Support Systems – globally provides our med-surg and specialty bed systems and surfaces, safe patient handling equipment and mobility solutions, as well as our clinical workflow solutions that deliver software and information technologies to improve care and deliver actionable insight to caregivers and patients.

Front Line Care – globally provides patient monitoring and diagnostic technologies, including a diversified portfolio of physical assessment tools that help diagnose, treat and manage a wide variety of illnesses and diseases, as well as a portfolio of vision care and respiratory care devices.

Surgical Solutions – globally provides products that improve surgical safety and efficiency in the operating room including tables, lights, pendants, positioning devices and various other surgical instruments and accessories.

Net Revenue

	Quarter Ended		Change As Reported		Constant Currency		U.S. Change As Reported		OUS Change As Reported	
	March 31 2019	2018								
Net Revenue:										
Product sales and service	\$636.5	\$610.7	4.2	%	6.4	%	12.6	%	(9.4))(3.6)%
Rental revenue	77.7	99.8	(22.1)	%	(21.2)	%	(23.5)	%	(11.2))(4.3)%
Total net revenue	\$714.2	\$710.5	0.5	%	2.5	%	5.8	%	(9.5))(3.7)%
Net Revenue:										
Patient Support Systems	\$359.6	\$355.0	1.3	%	3.0	%	7.4	%	(13.1))(7.2)%
Front Line Care	243.1	237.9	2.2	%	3.9	%	4.5	%	(2.8))(2.7)%
Surgical Solutions	111.5	117.6	(5.2)	%	(1.8)	%	2.2	%	(11.6))(5.2)%
Total net revenue	\$714.2	\$710.5	0.5	%	2.5	%	5.8	%	(9.5))(3.7)%

OUS - Outside of the United States

The following table reflects sales growth data for the quarter ended March 31, 2019 excluding the impacts of the adoption of ASC 606 to supplement our discussion and analysis of net revenue by quantifying and excluding the impact of the adoption of this rule for revenue streams and reporting segments:

Table of Contents

	Quarter Ended March 31 Adjusted 2019¹	2018	Change	Constant Currency	U.S. Change	OUS Change	Constant Currency
Net Revenue:							
Product sales and service	\$608.4	\$610.7	(0.4)%	1.9 %	5.2 %	(9.5)%	(3.7)%
Rental revenue	102.1	99.8	2.3 %	3.2 %	4.2 %	(11.2)%	(4.3)%
Total net revenue	\$710.5	\$710.5	— %	2.1 %	5.0 %	(9.6)%	(3.8)%

Net Revenue:							
Patient Support Systems	\$357.0	\$355.0	0.6 %	2.6 %	6.5 %	(13.3)%	(7.5)%
Front Line Care	242.0	237.9	1.7 %	3.2 %	3.8 %	(2.8)%	2.8 %
Surgical Solutions	111.5	117.6	(5.2)%	(1.8)%	2.2 %	(11.6)%	(5.2)%
Total net revenue	\$710.5	\$710.5	— %	2.1 %	5.0 %	(9.6)%	(3.8)%

OUS - Outside of the United States

¹Adjusted to remove the impacts of ASC 606. See Note 1, Summary of Significant Accounting Policies, and Note 2, Revenue Recognition, of our Condensed Consolidated Financial Statements in this Form 10-Q for additional information on the impact of adopting ASC 606.

	Year to Date Ended March 31 2019	2018	Change As Reported	Constant Currency	U.S. Change As Reported	OUS Change As Reported	Constant Currency
Net Revenue:							
Product sales and service	\$1,248.1	\$1,185.9	5.2 %	6.9 %	11.4 %	(5.2)%	(0.7)%
Rental revenue	149.6	194.3	(23.0)%	(22.4)%	(24.5)%	(11.1)%	(6.2)%
Total net revenue	\$1,397.7	\$1,380.2	1.3 %	2.8 %	4.7 %	(5.5)%	(1.0)%

Net Revenue:							
Patient Support Systems	\$700.6	\$689.4	1.6 %	3.0 %	4.7 %	(6.0)%	(1.3)%
Front Line Care	476.5	462.5	3.0 %	4.3 %	4.9 %	(1.1)%	3.0 %
Surgical Solutions	220.6	228.3	(3.4)%	(0.9)%	4.0 %	(9.7)%	(5.1)%
Total net revenue	\$1,397.7	\$1,380.2	1.3 %	2.8 %	4.7 %	(5.5)%	(1.0)%

OUS - Outside of the United States

The following table reflects sales growth data for the year to date period ended March 31, 2019 excluding the impacts of the adoption of ASC 606 to supplement our discussion and analysis of net revenue by quantifying and excluding the impact of the adoption of this rule for revenue streams and reporting segments:

Table of Contents

	Year to Date Ended March 31 Adjusted 2019¹	2018	Change	Constant Currency	U.S. Change	OUS Change	Constant Currency
Net Revenue:							
Product sales and service	\$1,196.0	\$1,185.9	0.9 %	2.6 %	4.4 %	(5.3)%	(0.8)%
Rental revenue	198.7	194.3	2.3 %	2.9 %	4.1 %	(11.1)%	(6.2)%
Total net revenue	\$1,394.7	\$1,380.2	1.1 %	2.6 %	4.4 %	(5.6)%	(1.0)%
Net Revenue:							
Patient Support Systems	\$699.2	\$689.4	1.4 %	2.9 %	4.5 %	(6.2)%	(1.3)%
Front Line Care	474.9	462.5	2.7 %	3.8 %	4.4 %	(1.1)%	3.0 %
Surgical Solutions	220.6	228.3	(3.4)%	(0.9)%	4.0 %	(9.7)%	(5.1)%
Total net revenue	\$1,394.7	\$1,380.2	1.1 %	2.6 %	4.4 %	(5.6)%	(1.0)%

OUS - Outside of the United States

¹Adjusted to remove the impacts of ASC 606. See Note 1, Summary of Significant Accounting Policies, and Note 2, Revenue Recognition, of our Condensed Consolidated Financial Statements in this Form 10-Q for additional information on the impact of adopting ASC 606.

Consolidated Revenue

Product sales and service revenue increased 4.2% and 5.2% on a reported basis, or 6.4% and 6.9% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019 primarily due to the reclassification of \$23.3 million and \$47.5 million of certain revenue streams to Product sales and services for the quarter and year to date periods ended March 31, 2019 as a result of adopting ASC 606, as well as strong new product growth in the United States. New product growth was partly offset by a second quarter decline in Canada and the Middle East due to large projects in the prior year.

Rental revenue decreased 22.1% and 23.0% on a reported basis, or 21.2% and 22.4% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019 primarily due to the reclassification of \$23.3 million and \$47.5 million of certain revenue streams to Product sales and services for the quarter and year to date periods ended March 31, 2019 as a result of adopting ASC 606 as well as the divestiture of our third-party rental business in fiscal 2018.

Excluding the impact of adopting ASC 606, revenue was flat and increased 1.1% on a reported basis, or increased 2.1% and 2.6% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019, primarily due to strong new product growth. New product growth was partly offset by a second quarter decline in Canada and the Middle East due to large projects in the prior year.

Business Segment Revenue

Patient Support Systems revenue increased 1.3% and 1.6% on a reported basis, or 3.0% and 3.0% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods. The increases in the quarter and year to date periods were driven by strong growth in med-surg frames, clinical workflow solutions and safe patient handling equipment in the United States. Growth in the United States was partly offset by OUS declines in Canada and the Middle East due to large projects in the prior year. Revenue was also higher by \$2.6

million and \$1.4 million for the quarter and year to date periods ended March 31, 2019 under ASC 606 in comparison to previous accounting guidance. Under ASC 606 the performance obligation for revenue related to certain products was determined to be a fully installed system whereas historically, this obligation was accounted for as a multiple element arrangement and revenue was recognized upon delivery of hardware and software and the remainder when installation was complete.

Table of Contents

Front Line Care revenue increased 2.2% and 3.0% on a reported basis, or 3.9% and 4.3% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods. These improvements were primarily due to strong growth in our respiratory care business due to the launch of new products. Revenue was also higher by \$1.1 million and \$1.6 million for the quarter and year to date periods ended March 31, 2019 under ASC 606 in comparison to previous accounting guidance. Revenue related to certain products is required to be accelerated under ASC 606 compared to historical practice as we have no on-going performance obligation after delivery of the product to the customer, whereas previously this revenue was recognized over the period the Company was reimbursed by third parties.

Surgical Solutions revenue decreased 5.2% and 3.4% on a reported basis, or 1.8% and 0.9% on a constant currency basis, for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods. These decreases were mainly due to the exit of certain product lines and timing of large projects in the prior year period.

Gross Profit

	Quarter Ended March 31		Year to Date Ended March 31	
	2019	2018	2019	2018
Gross Profit				
Product sales and service	\$313.8	\$297.0	\$609.1	\$568.1
<i>Percent of Related Net Revenue</i>	49.3	% 48.6	% 48.8	% 47.9
Rental	38.8	53.4	73.5	101.9
<i>Percent of Related Net Revenue</i>	49.9	% 53.5	% 49.1	% 52.4
Total Gross Profit	\$352.6	\$350.4	\$682.6	\$670.0
<i>Percent of Total Net Revenue</i>	49.4	% 49.3	% 48.8	% 48.5

Product sales and service gross margin increased 70 and 90 basis points for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods primarily due to product mix and the reclassification of products previously classified as rental revenue due to the adoption of ASC 606.

Rental gross margin decreased 360 and 330 basis points for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods primarily due to the reclassification of products previously classified as rental revenue due to the adoption of ASC 606.

Operating Expenses

	Quarter Ended March 31		Year to Date Ended March 31	
	2019	2018	2019	2018
Research and development expenses	\$36.6	\$34.7	\$69.8	\$67.0
<i>Percent of Total Net Revenue</i>	5.1	% 4.9	% 5.0	% 4.9
Selling and administrative expenses	\$231.2	\$232.7	\$449.2	\$454.4
<i>Percent of Total Net Revenue</i>	32.4	% 32.8	% 32.1	% 32.9

Research and development expenses increased 5.5% and 4.2% for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods due to continued investment in new products. As a percentage of revenue, research and development expenses remained relatively consistent.

As a percentage of total net revenue, selling and administrative expenses decreased in the quarter and year to date periods ended March 31, 2019 compared to the prior year periods. Selling and administrative expenses include acquisition-related intangible asset amortization, acquisition and integration costs and costs related to tax law changes totaling \$32.2 million and \$60.9 million for the quarter and year to date periods ended March 31, 2019. Selling and administrative expenses include acquisition-related intangible asset amortization, acquisition and integration costs and significant litigation related costs totaling \$32.2 million and \$65.3 million for the quarter and year to date periods ended March 31, 2018. Excluding these items, as a percentage of total

Table of Contents

revenue, selling and administrative expenses decreased 0.7% and 0.2% for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods due to cost reductions from ongoing business optimization initiatives.

Business Segment Divisional Income

	Quarter		Change	Year to Date		Change
	Ended March 31 2019	2018		Ended March 31 2019	2018	
Divisional income:						
Patient Support Systems	\$69.8	\$67.2	3.9 %	\$126.6	\$120.6	5.0 %
Front Line Care	67.1	60.5	10.9 %	127.0	115.9	9.6 %
Surgical Solutions	15.1	15.5	(2.6)%	26.4	25.2	4.8 %

Refer to Note 14 of our Condensed Consolidated Financial Statements in this Form 10-Q for a description of how divisional income is determined.

Patient Support Systems divisional income increased 3.9% and 5.0% for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods primarily due to revenue growth in the United States and lower operating expenses as a percentage of revenue.

Front Line Care divisional income increased 10.9% and 9.6% for the quarter and year to date periods ended March 31, 2019 compared to the prior year periods as a result of revenue growth and higher margins from new products.

Surgical Solutions divisional income decreased 2.6% for the quarter ended March 31, 2019 but increased 4.8% for the year to date period compared to the prior year period as revenue declines due to the exit of certain product lines and the timing of large projects were offset by strong first quarter growth in the United States and operating expense reductions.

Special Charges and Other

	Quarter Ended		Year to Date	
	March 31 2019	2018	March 31 2019	2018
Special charges	\$3.5	\$36.9	\$11.5	\$50.4
Interest expense	\$(21.8)	\$(24.2)	\$(43.1)	\$(47.3)
Investment income and other, net	\$1.2	\$(0.4)	\$1.3	\$1.4

In connection with various organizational changes to improve our business alignment and cost structure, we recognized Special charges of \$3.5 million and \$36.9 million for the quarters ended March 31, 2019 and 2018, and \$11.5 million and \$50.4 million for the year to date periods ended March 31, 2019 and 2018. These charges relate to the initiatives described in Note 9 of our Condensed Consolidated Financial Statements in this Form 10-Q.

Interest expense was lower in the quarter and year to date periods ended March 31, 2019 due to a decrease in long-term debt compared to the prior year periods and the impact of our cross-currency swaps entered into in July 2018. See Note 6 of our Condensed Consolidated Financial Statements in this Form 10-Q for additional information.

Investment income and other, net increased in the quarter ended March 31, 2019 primarily due to favorable movements in foreign exchange rates. Investment income and other, net remained relatively flat in the year to date period ended March 31, 2019.

Income Tax Expense

The effective tax rate for the quarter ended March 31, 2019 was 18.5% compared to (32.6)% for the comparable period in the prior year due primarily to the difference in the discrete tax benefits realized in each period. The current period rate was favorably impacted by \$1.4 million of discrete tax benefits primarily related to excess tax benefits on deductible stock compensation. This compares to \$11.2 million of discrete tax benefits in the comparable prior year period which primarily related to a change in tax accounting method for historical currency losses.

Table of Contents

The effective tax rate for the year to date period ended March 31, 2019 was 16.9% compared to (123.3)% for the comparable period in the prior year due primarily to tax benefits recorded in the prior period related to the Tax Act. The year to date period rate was favorably impacted by \$4.5 million of discrete tax benefits primarily related to \$2.4 million of excess tax benefits on deductible stock compensation. This compares to \$75.6 million of discrete tax benefits in the prior year to date period primarily related to the Tax Act and a change in tax accounting method for historical currency losses.

The adjusted effective tax rate for the quarter and year to date periods ended March 31, 2019 was 20.4% and 20.1% compared to 21.4% and 20.4% for the prior year periods. The lower adjusted tax rate in the current year is primarily due to the reduction in the U.S. federal corporate tax rate from Tax Act legislation partially offset by lower current year discrete tax items primarily related to the excess tax benefits on deductible stock compensation.

Earnings per Share

Diluted earnings per share increased from \$0.42 to \$0.74 for the quarter ended March 31, 2019 primarily due to a reduction in Special charges in the current quarter as compared to the prior year period. Our diluted earnings per share was higher by \$0.04 in the quarter ended March 31, 2019 as a result of the adoption of ASC 606. Diluted earnings per share decreased from \$1.73 to \$1.36 for the year to date period ended March 31, 2019 primarily due to the recognition of incremental tax benefits in the year to date period ended March 31, 2018 primarily due to the Tax Act as disclosed in Note 10 of our Condensed Consolidated Financial Statements in this Form 10-Q. Our diluted earnings per share was higher by \$0.03 in the year to date period ended March 31, 2019 as a result of the adoption of ASC 606.

GAAP and Adjusted Earnings

Operating margin, income before income taxes, income tax expense, and earnings attributable to common shareholders per diluted share are summarized in the table below. GAAP amounts are adjusted for certain items to aid management in evaluating the performance of the business. Income tax expense is computed by applying a blended statutory tax rate based on the jurisdictional mix of the respective before tax adjustment.

	Quarter Ended March 31, 2019			Quarter Ended March 31, 2018				
	Operating Margin	Income Before Taxes	Income Tax Expense	Diluted EPS ¹	Operating Margin	Income Before Taxes	Income Tax Expense	Diluted EPS ¹
GAAP Basis	11.4 %	\$ 60.7	\$ 11.2	\$ 0.74	6.5 %	\$ 21.5	\$ (7.0)	\$ 0.42
Adjustments:								
Acquisition and integration costs	0.2 %	1.6	0.3	0.02	0.4 %	2.6	0.7	0.03
Acquisition-related intangible asset amortization	3.8 %	27.3	6.4	0.31	3.8 %	27.0	6.9	0.30
Regulatory compliance costs	0.5 %	3.3	0.9	0.04	0.1 %	0.8	0.2	0.01
Litigation expenses	— %	—	—	—	0.3 %	1.8	0.4	0.02
Special charges	0.5 %	3.5	0.9	0.04	5.2 %	36.9	9.7	0.40
Tax law and method changes	— %	—	—	—	— %	—	8.5	(0.12)
Adjusted Basis	16.4 %	\$ 96.4	\$ 19.7	\$ 1.14	16.2 %	\$ 90.6	\$ 19.4	\$ 1.05

¹ Total does not add due to rounding.

Table of Contents

	Year to Date Ended March 31, 2019			Year to Date Ended March 31, 2018				
	Operating Margin	Income Before Income Taxes	Income Tax Expense	Diluted EPS	Operating Margin	Income Before Income Taxes	Income Tax Expense	Diluted EPS ¹
GAAP Basis	10.9 %	\$ 110.3	\$ 18.6	\$ 1.36	7.1 %	\$52.3	\$(64.5)	\$ 1.73
Adjustments:								
Acquisition and integration costs	0.1 %	1.8	0.4	0.02	0.3 %	4.6	1.2	0.05
Acquisition-related intangible asset amortization	3.8 %	53.0	12.3	0.60	3.9 %	53.7	13.5	0.60
Regulatory compliance costs	0.4 %	6.1	1.6	0.07	0.1 %	1.2	0.3	0.01
Litigation expenses	— %	—	—	—	0.4 %	5.8	1.5	0.06
Special charges	0.8 %	11.5	2.8	0.13	3.7 %	50.4	13.2	0.55
Tax law and method changes	— %	—	1.0	(0.02)	— %	—	68.8	(1.01)
Gain on disposition	— %	—	—	—	— %	(1.0)	—	(0.01)
Adjusted Basis	16.1 %	\$ 182.7	\$ 36.7	\$ 2.16	15.5 %	\$ 167.0	\$ 34.0	\$ 1.97

¹ Total does not add due to rounding.

Liquidity and Capital Resources

	Year to Date Ended March 31	
	2019	2018
Cash Flows Provided By (Used In):		
Operating activities	\$158.2	\$125.6
Investing activities	(71.8)	(47.7)
Financing activities	(80.1)	(75.8)
Effect of exchange rate changes on cash	(2.3)	5.1
Increase in Cash and cash equivalents	\$4.0	\$7.2

Operating Activities

Cash provided by operating activities increased \$32.6 million compared to the prior year due to higher operating profit and working capital improvements. Net income in the prior year period was impacted by the non-cash incremental tax benefits recorded related to the Tax Act, offset by a net loss on disposition of businesses of \$22.4 million. See Note 10 and Note 9 of our Condensed Consolidated Financial Statements in this Form 10-Q for information on the Tax Act and the net loss on disposition.

Investing Activities

Cash used in investing activities increased \$24.1 million compared to the prior year, primarily due to our acquisition of non-marketable equity securities of \$26.6 million, as well as our acquisition of the right to use patented technology and certain related assets from a supplier in our Front Line Care segment of \$17.1 million, as described in Note 3 and Note 4 of our Condensed Consolidated Financial Statements in this Form 10-Q. This increase was partially offset by lower capital expenditures of \$20.0 million in the year to date period ended March 31, 2019 compared to the prior year.

Table of Contents

Financing Activities

Cash used in financing activities was \$80.1 million in the year to date period ended March 31, 2019, primarily driven by purchases of our common stock under our share repurchase program of \$75.0 million as described in Note 12 of our Condensed Consolidated Financial Statements in this Form 10-Q as well as dividend payments. These cash uses were partly offset by net borrowings on our various borrowing facilities of \$14.0 million. For the year to date period ended March 31, 2018, cash used in financing activities was \$75.8 million, primarily driven by net payments on our various borrowing facilities of \$60.8 million and dividend payments. See Note 6 of our Condensed Consolidated Financial Statements in this Form 10-Q for information on our financing agreements.

Other Liquidity Matters

We believe that cash on hand and cash generated from operations, along with amounts available under our Revolving Credit Facility and Securitization Program, will be sufficient to fund operations, working capital needs, capital expenditure requirements, and financing obligations for at least the next twelve months. Our \$700.0 million Revolving Credit Facility is with a syndicate of banks, which we believe reduces our exposure to any one institution and would still leave us with significant borrowing capacity in the event that any one of the institutions within the group is unable to comply with the terms of our amended and restated credit agreement. However, disruption and volatility in the credit markets could impede our access to capital.

On April 1, 2019, we completed the acquisition of Voalte, Inc. (“Voalte”), a clinical communications software company, for consideration of \$180.0 million, subject to certain post-closing adjustments that may change the purchase price, and committed to up to an additional \$10.0 million in earnout payments related to the achievement of certain commercial milestones. We paid \$178.1 million on April 1, 2019, which consisted of the consideration of \$180.0 million plus cash acquired of \$9.6 million, less debt assumed of \$9.0 million and lower working capital of \$2.5 million.

In addition to the discussion of our financing agreements and share repurchases detailed in Note 6 and Note 12 of our Condensed Consolidated Financial Statements in this Form 10-Q, our primary pension plan invests in a variety of equity and debt securities. As of September 30, 2018, our latest measurement date, our pension plans were underfunded by approximately \$54.8 million. Based on our current funded status, we are not required to make any contributions to our primary pension plan in fiscal 2019.

We intend to continue to pay quarterly cash dividends comparable to those paid in the periods covered by these financial statements. However, the declaration and payment of dividends by us will be subject to the sole discretion of our Board and will depend upon many factors, including our financial condition, earnings, capital requirements, covenants associated with debt obligations, legal requirements, and other factors considered relevant by our Board.

Over the long term, we intend to continue to pursue inorganic growth in certain areas of our business, but the timing, size or success of any acquisition effort and the related potential capital commitments cannot be predicted.

As of March 31, 2019, approximately 76.7% of our cash and cash equivalents were held by our foreign subsidiaries. As of March 31, 2019, our practice and intention was to reinvest the earnings in our non-U.S. subsidiaries outside of the United States.

The U.S. Internal Revenue Service and Treasury Department continue to release proposed guidance with respect to the Tax Act. We continue to evaluate what impact, if any, each piece of guidance may have on our related tax positions and our effective tax rate if, and when, such guidance is finalized.

Contractual Obligations and Contingent Liabilities and Commitments

There have not been any significant changes since September 30, 2018 impacting our contractual obligations and contingent liabilities and commitments.

Critical Accounting Policies

Our accounting policies require management to make significant estimates and assumptions using information available at the time the estimates are made. Such estimates and assumptions significantly affect various reported amounts of assets, liabilities, revenue, and expenses. If future experience differs materially from these estimates and assumptions, our results of operations and financial condition could be affected. A detailed description of our accounting policies is included in Note 1 of our Consolidated Financial Statements and the Critical Accounting Policies Section of Management's Discussion and Analysis of Financial Condition and Results of Operations included in our 2018 Form 10-K. With the exception of our new revenue recognition policy disclosed in Note 1 of our Condensed Consolidated Financial Statements in this Form 10-Q, there have been no material changes to such policies since September 30, 2018.

Table of Contents

For a further summary of certain accounting policies and estimates and recently issued accounting pronouncements applicable to us, see Note 1 of our Condensed Consolidated Financial Statements in this Form 10-Q.

39

Table of Contents

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

We are exposed to various market risks, including fluctuations in interest rates, collection risk associated with our accounts and notes receivable portfolio and variability in currency exchange rates. We have established policies, procedures, and internal processes governing our management of market risks and the use of financial instruments to manage our exposure to such risks.

We are subject to variability in foreign currency exchange rates in our international operations. Exposure to this variability is managed primarily through the use of natural hedges, whereby funding obligations and assets are both managed in the local currency. From time-to-time, we enter into currency exchange agreements, including forward contracts and cross-currency swaps, to manage exposures arising from fluctuating exchange rates related to specific and forecasted transactions. We operate this program pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. The sensitivity of earnings and cash flows to variability in exchange rates is assessed by applying an appropriate range of potential rate fluctuations to our assets, obligations and projected results of operations denominated in foreign currencies. The maximum length of time over which we hedge transaction exposures is generally 15 months. Derivative gains and losses when initially reported as a component of Accumulated other comprehensive income (loss) are reclassified to earnings in the period when the transaction affects earnings.

Refer to Note 6 of our Condensed Consolidated Financial Statements in this Form 10-Q for discussions and quantitative disclosures about our derivative agreements.

For additional information on market risks related to our pension plan assets, see Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our 2018 Form 10-K.

Item 4. CONTROLS AND PROCEDURES

Our management, with the supervision and participation of our President and Chief Executive Officer and our Senior Vice President and Chief Financial Officer (the “Certifying Officers”), has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2019. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and such information is accumulated and communicated to management, including our Certifying Officers and our Board of Directors, as appropriate to allow timely decisions regarding required disclosure. Based upon that evaluation, the Certifying Officers concluded that our disclosure controls and procedures were effective as of March 31, 2019.

There have been no changes to our internal controls over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred in our most recent completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents**PART II – OTHER INFORMATION****Item 1. LEGAL PROCEEDINGS**

Refer to Note 15 of our Condensed Consolidated Financial Statements in this Form 10-Q for further information on our legal proceedings.

Item 1A. RISK FACTORS

There have been no material changes to our risk factors as disclosed in “Item 1A. Risk Factors” in our 2018 Form 10-K for the year ended September 30, 2018.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

<u>Period</u>	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Programs (2)
January 1, 2019 - January 31, 2019	1,981	\$89.39	—	\$ 89.7
February 1, 2019 - February 28, 2019	487	\$94.64	—	\$ 89.7
March 1, 2019 - March 31, 2019	3,222	\$104.67	—	\$ 89.7
Total	5,690		—	

(1) Shares purchased in the quarter ended March 31, 2019 were in connection with employee payroll tax withholding for restricted stock distributions.

In September 2013, the Board approved an expansion of its previously announced share repurchase authorization to a total of \$190.0 million. In November 2017, the Board approved an increase to the share repurchase program in (2) an amount of \$150.0 million. As of March 31, 2019, a cumulative total of \$250.3 million had been used, leaving us with availability of \$89.7 million under the share repurchase programs. The program does not have an expiration date and currently there are no plans to terminate this program in the future.

Table of Contents

Item 6. EXHIBITS

A. Exhibits

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema Document

101.CAL XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB XBRL Extension Labels Linkbase Document

101.DEF XBRL Taxonomy Extension Definition Linkbase Document

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

42

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HILL-ROM HOLDINGS, INC.

(Registrant)

DATE: April 26, 2019 By: /s/ Barbara W. Bodem
Name: Barbara W. Bodem
Title: Senior Vice President and Chief Financial Officer
(duly authorized officer and principal financial officer)